SOCRA CCRP EXAM STUDY GUIDE 2026-2027

Avoid exposing participants or other blinded staff to distinguishing packaging, and promptly notify the investigator and sponsor of the potential blind compromise. Follow authorized procedures for segregating or correcting affected stock and document which participants and personnel may have been exposed. Do not relabel products informally or assume the blinding risk is harmless.

Separate incompatible roles or restrict permissions so the assessor cannot access information that could bias endpoint evaluation; document the revised blinding and escalation arrangements.

No. Bottle openings may occur without ingestion, and diary entries may be incomplete or mistaken. Preserve both original data sources, reconcile possible causes through a neutral participant discussion and accountability review, and determine whether a clinically important dosing error occurred. Follow predefined adherence-assessment methods rather than editing one data stream to match the other. Report any relevant deviations and interpret the findings according to each measure's limitations.

Determine whether the event occurred during the protocol's required safety-collection period, whether any research procedure could have contributed, and whether it affects eligibility or immediate care. An illness before drug exposure generally cannot be caused by that drug, but it may still be an adverse event or other reportable occurrence under the approved plan. Document the true onset, exposure status, and investigator assessment. Do not erase it merely because dosing has not begun, or falsely attribute it to study treatment.

Reassess all relevant inclusion and exclusion criteria at the protocol-defined enrollment decision, alert the investigator, and determine whether a permitted washout or rescreening process is available. Do not randomize on the assumption that eligibility established during screening remains unchanged.

The result is outside the defined eligibility window and cannot be treated as current by changing its date. Arrange a repeat test as permitted by the protocol and consent, verify eligibility using valid results, and document the screening outcome before randomization.

Verify the information with the participant or an authorized contact as appropriate, reassess the participant's wishes and ability to continue, and check whether the protocol permits a different visit location or assessment method. Protect the reliability of the specified outcome and the participant's safety, arranging appropriate approved follow-up where feasible. Record a missed or modified assessment honestly rather than completing an onsite assessment field with data from a non-equivalent method.

The drug has reached a person not authorized to receive it, implicating the investigator's obligation to control investigational drug under 21 CFR 312.61. Prioritize immediate medical assessment of the caregiver and the participant as appropriate, secure the remaining medication, and notify the investigator and sponsor under applicable procedures. Document the exposure, accountability discrepancy, and any safety reports without recording the caregiver's dose as participant adherence.

Selective access based on presumed efficacy could violate the approved allocation and treatment plan, compromise blinding, introduce selection bias, and disadvantage participants. The site must escalate the shortage to the sponsor and responsible investigator, preserve randomization and authorized dispensing rules, and assess continuity of treatment and participant risks. Any change in allocation, treatment availability, or protocol procedures requires appropriate scientific, ethical, and regulatory review. Document shortages and decisions rather than manipulating kit assignment to hide an operational problem.

Maintain the preliminary result, the amended authenticated result, their issue times, and the reason for correction, with a clear link to the participant and visit. Promptly have the investigator reassess clinical consequences and whether further care, adverse-event reporting, or dosing decisions are needed. Update the eCRF through an attributable correction, not deletion of the original. Preserve evidence that the earlier clinical decision relied on the result available at that time.

Preserve the true collection and processing times and record the processing failure. Seek a laboratory assessment of specimen acceptability and the investigator's assessment of any impact on safety or eligibility; recollect only when authorized and feasible. Do not silently use a potentially invalid result to support a major trial decision.

Apply documented change control and risk-based testing for field definitions, units, identifiers, missing values, and error handling. Validate or qualify the mapping as appropriate, reconcile sample records and critical results, and maintain old and new transfer specifications. Do not assume the revised interface is equivalent just because files load without an error message.

Confirm the source result and units, determine whether an import, decimal-place, or mapping error occurred, and assess any clinical decisions already based on the incorrect number. Correct the electronic record through authorized, traceable processes, validate the transfer fix, and review other potentially affected records rather than patching only the discovered value.

Check the approved data-transfer specification, laboratory source files, units, reference intervals, specimen identifiers, and transformation rules. Resolve missing or inconsistent units with the laboratory and data management team and document any conversions and their verification. Preserve the original transferred values and records of the correction so reviewers can reproduce the final analysis dataset. Incorrect unit mapping may create false clinical outliers or conceal important results. A final transfer is not validated merely because it arrived on time.

Reassess the participant's legal capacity and the consent basis for the ongoing research. When the participant becomes an adult capable of consent, their own informed consent is generally needed for further research interactions or interventions unless an appropriate regulatory waiver or other lawful basis applies. Use the currently approved materials and explain the remaining procedures, risks, and withdrawal options. Do not treat childhood assent and earlier parental permission as automatically authorizing every activity after the age of majority; document the new consent decision.

Determine whether the scans are complete, accurate, readable, appropriately attributable copies retaining all relevant context and signatures, with reliable evidence of when and how they were produced. Record the damage, the loss of originals, and the controls over surviving files, and notify responsible parties as required. ICH E6(R3) permits suitable certified copies, but a casual unverified scan should not be represented as a certified original equivalent. Preserve the incident trail and assess whether missing information affects safety or reliability.

Distinguish the end of recruitment from the end of research activities requiring oversight. Determine whether participants are still being contacted, receiving study interventions, or undergoing protocol-directed data collection, and review the IRB's closure criteria and applicable law. Continuing follow-up can mean the protocol remains active even with enrollment permanently closed. Tell the IRB accurately what work remains, maintain required approvals or other oversight status, and do not use an administrative closure designation to bypass participant-protection or reporting requirements.

Once allocated, packaged, and distributed as part of the investigational plan, comparator supplies must be controlled according to the trial's specified treatment, blinding, storage, and accountability procedures. Record lot and kit identity, receipt, dispensing, returns, and disposition to the extent required. Separate blinded comparator stock from clinical inventory to prevent unintended substitution or disclosure. Its original marketing status does not eliminate the need to trace which trial participant received which study treatment.

Appropriate alternative procedures or courses of treatment that may benefit the prospective participant must be described, along with the other basic consent elements (21 CFR 50.25(a)(4)).

Determine whether subcontracting is permitted under the applicable agreements, whether responsibilities are documented, and whether the subcontractor has appropriate qualifications, protections, and access controls. The sponsor should oversee important transferred work, including work further subcontracted, and retain access to information needed to assess quality and data reliability. Missing arrangements should be corrected before relying on the output.

Confirm that the site's reviewing IRB, whether local or designated single IRB, has approved or formally authorized the applicable consent version before use, subject to any specific immediate-hazard requirements. Check the approved language, local contact details, version and date, and effective instructions for new and already enrolled participants. Sponsor distribution alone is not ethics approval at every site. Keep superseded forms from use and document when staff were trained and when the new form became valid for that site.

Use only a lawful, institutionally and IRB-permitted method of accessing records and approaching potential participants, protect identifiable information, and distinguish prescreening from research-specific assessments. Protocol-required procedures generally need consent first unless an applicable consent waiver or exception authorizes them.

Shared credentials conceal who performed the work and undermine attributable entries, permission controls, and electronic audit trails. Require individual authorized accounts, preserve existing audit evidence, investigate impacted records, and correct the workflow; do not attribute one person's work to another user's signature.

Refuse to fabricate an observation. Recheck the source record, obtain legitimately missing information if it can still be collected under the protocol and consent, and otherwise use the approved missing-data status with a documented explanation. Notify data management if the proposed recoding would affect the endpoint or bias the analysis. The statistical team must apply the prespecified analysis and missing-data rules, not manufacture a value to meet the lock timetable. An accurate unresolved value is preferable to a knowingly false completed field.

Preserve the original eligibility evidence and true sequence of screening, authorization, treatment, and discovery. Notify the investigator and sponsor, evaluate immediate participant risks and protocol deviations, and correct data only to reflect substantiated facts with an audit trail. Analysis-population decisions belong under the prespecified statistical rules and appropriate review, not retrospective alteration of source history. Investigate whether the process failure is isolated or indicates a systematic enrollment-control problem.

Check legitimate contemporaneous records for a verifiable time, then provide the supported value or state that it is unavailable with the documented reason. Reply to the query transparently, correct records only under controlled procedures, and never estimate or invent a time to clear a database edit check.

The sponsor and responsible investigator must promptly evaluate the recommendation and implement applicable trial safety actions according to the charter, protocol, and regulatory obligations. Inform sites and oversight bodies as appropriate without revealing unnecessary unblinded data. Record the recommendation, authorized decision, communications, and instructions affecting participants.

No. Edit checks identify records needing review; they do not authorize altering true findings. Confirm the value, units, specimen, and source documentation, then resolve or annotate the query according to controlled procedures while preserving the authentic result. An extreme but valid value may be clinically important and must remain available for safety review and analysis.

Verify the replacement's qualifications and task-specific readiness before assignment, arrange appropriate investigator oversight, and update the delegation record where warranted by the significance of the work. Revoke the departed nurse's access and preserve prior records. Assess procedures performed during any gap in authorization or training, including effects on participants and data, rather than merely inserting new names into the log later.

Safeguard the participant and assess whether the device can be used safely, preserve device identifiers and event data, and notify the sponsor under the investigational plan. Document the malfunction and evaluate whether it is a device deficiency, protocol deviation, or reportable safety concern; absence of injury does not justify ignoring it.

Under 21 CFR 812.46(b)(2), the sponsor must end the investigations, or affected portions, as soon as possible and no later than 5 working days after making the unreasonable-risk determination and no later than 15 working days after first receiving notice of the effect. Both limits apply. Immediate participant protection and communication cannot wait for either deadline, and the sponsor should document its evaluation, decision, and required notifications.

Under 21 CFR 812.150(b)(1), the sponsor must report the results of the evaluation to FDA, all reviewing IRBs, and participating investigators within 10 working days after the sponsor first receives notice of the effect. Section 812.46(b)(1) separately requires the sponsor to evaluate the effect immediately. The reporting clock is based on initial notice, not a later date selected for completing an internal committee review.

Under 21 CFR 812.150(b)(2), the sponsor must notify FDA, all reviewing IRBs, and participating investigators within 5 working days after receiving the withdrawal-of-approval notice. Promptly communicate operational instructions to prevent further unauthorized use and protect participants already exposed to the device. This five-working-day sponsor clock is separate from the investigator's duty to inform the sponsor after a withdrawal affecting that investigator's part of the trial.

Record the true administration time, assess any safety or pharmacokinetic impact, and classify and report the deviation using the protocol and sponsor/IRB requirements. Do not alter timestamps to make the dose appear compliant; determine whether a schedule or process change is needed to prevent recurrence.

Preserve both observations with their source, time, device, and measurement context; alert the investigator if one suggests a clinical concern. Apply the protocol's rules for the safety assessment and endpoint rather than selecting the more convenient number. Raise a data-system question if the eCRF cannot capture required distinctions. When a corrected or adjudicated value is appropriate, keep the original readings and documented basis for the decision traceable.

The safety escalation and communication pathway has failed. Promptly assess whether the participant requires medical action, notify the responsible investigator, investigate the delay, and implement corrective steps. Review service agreements, notification thresholds, contact trees, coverage, and evidence of receipt. Reporting a value into a database is not a substitute for getting urgent clinical information to someone who can act.

Do not use an unverified substitute kit simply to keep the appointment on schedule. Confirm the required tube, additive, labeling, handling instructions, and assay compatibility with the approved laboratory procedures. Escalate to the investigator and vendor coordinator, arrange a correct collection when clinically and operationally appropriate, and document the missed window or deviation. Participant safety and usable specimen identity take precedence over a cosmetically complete visit record.

Review the number of patients with the required biomarker who also meet the protocol's other criteria, can be contacted appropriately, and are likely to consent; overall diagnosis counts alone are unreliable.

Handle the event under both processes when their criteria apply. The investigator reports serious adverse events to the sponsor as required and ensures appropriate medical follow-up; separately, the site supplies endpoint documentation for trial adjudication. Sponsor regulatory safety reporting depends on applicable causality, expectedness, and other criteria. A pending adjudication decision must not delay a required safety notification.

Preserve the authenticated result, its units, collection date, laboratory method, and the reference interval applicable when the result was issued. Confirm whether the new interval reflects an assay change, population update, or correction, and make sure medical and endpoint algorithms apply an authorized, documented rule. Reassess affected safety alerts and derived values, with investigator review if needed. Do not rewrite historical laboratory reports or apply the latest interval retroactively without scientific and documented justification.

Identify the physician's trial-related role, qualifications, instructions, and reporting route within the sponsor and investigator's documented arrangements. Ensure the medically responsible investigator receives clinically important findings promptly and has access to an attributable record of what the local physician actually assessed. Delegating or arranging activities outside the main site does not eliminate the investigator's responsibility for participant safety and oversight of activities under that investigator's control.

The IRB, not the investigator alone, may waive or alter consent under 21 CFR 50.22 only after documenting all required findings: minimal risk, impracticability, any need for identifiable data/specimens, protection of rights and welfare, and later information when appropriate.

Promptly assess whether valid consent was obtained and documented before participation, protect the participant, and inform the investigator and sponsor. Evaluate reporting to the IRB and other authorities according to requirements, document an accurate investigation and remediation, and never backdate or procure a misleading signature.

Provide only the authorized, secure level of direct access needed to verify trial conduct and data, consistent with consent, privacy law, agreements, and monitoring procedures. Use individual permissions, maintain appropriate access logs, and do not send uncontrolled copies of participant records by ordinary email.

Track each written finding to its owner, deadline, documented investigation or correction, and evidence of closure. Clarify disagreements promptly and provide the sponsor or monitor the supporting records; verbal discussion alone does not establish that an identified problem was resolved. Prioritize items affecting participant safety, rights, or critical trial data.

Request the underlying monitoring documentation, evaluate unresolved issues and their impact, and require timely remediation with verifiable completion. Reassess contractor performance and oversight arrangements, escalating serious noncompliance as required. Completion counts alone do not establish adequate monitoring; the sponsor needs evidence that significant findings were recognized, communicated, and addressed.

No. Escalate and contain the risk immediately, assess affected participants, and follow required clinical, sponsor, and ethics or regulatory notifications. The sponsor should adjust monitoring intensity or methods proportionately and verify corrective action. A predefined visit calendar is not a reason to postpone urgent risk control.

Prioritize the missing toxicity tests because they may affect immediate dosing decisions and participant safety. Notify the medically responsible investigator, determine whether any participants require assessment, and investigate the extent and cause. Delayed routine data entry should still be addressed, but ICH E6(R3) supports allocating effort according to risk to participants and reliability of critical trial results.

No. A global last-participant-last-visit milestone does not automatically mean that every site's participant obligations, data activities, or closeout requirements are complete. Check the protocol's definition of study end and confirm remaining safety follow-up, reporting, queries, accountability, and IRB/IEC obligations. Document the status of each open item, assign owners and deadlines, and arrange safe continued contact or care. A site closeout visit can be planned while identified tasks are being resolved, but staff must not certify an activity as complete merely because a sponsor has announced an operational milestone.

Investigate why the quality tolerance limit was exceeded, whether the problem is concentrated at certain sites or affects the trial more broadly, and what it means for participant protection or reliability of the primary analysis. Document the evaluation, implement suitable mitigation, and reassess its effectiveness. The sponsor should not simply raise the limit after seeing an unfavorable result to make the metric appear compliant.

A default negative response can be mistaken for an affirmative assessment and systematically underreport events, especially when a form is opened but not completed. Review how the field is populated, saved, and signed; identify affected records; and cross-check original safety assessments. Correct the system design or workflow through controlled change and testing, with retraining as appropriate. A blank or not-assessed state should not silently become documented evidence that no event occurred.

Record the medication, dose, start date, and indication; promptly have the investigator assess interaction risks and protocol restrictions. Contact the treating clinician as appropriate and obtain participant permission where required. Implement a medically appropriate plan, including any authorized treatment interruption, and document relevant protocol deviations or safety findings.

Protect the participant first. A change needed to eliminate an apparent immediate hazard may be implemented immediately rather than waiting for prior IRB approval; for an IND protocol change under 21 CFR 312.30(b)(2)(ii), FDA is then notified by protocol amendment and the IRB is notified under applicable procedures. Document the hazard, the change, its timing, the medical reasoning, and required reports. This is not a general exception for convenience.

No. Under section 812.150(b)(7), the sponsor of a non-significant-risk device investigation must submit a final report to all reviewing IRBs within six months after termination or completion; that provision does not impose the same FDA completion notice and FDA final report specified for significant-risk investigations. Other duties may still apply under the protocol, another regulation, an FDA request, or institutional policy. Determine and document the correct device-risk status and applicable reporting requirements rather than copying the significant-risk workflow uncritically.

No single rule demands that every data field be nonmissing before lock. Apply the approved data-management plan and a documented, risk-proportionate decision process that considers the query's relevance to participant safety, trial eligibility, important outcomes, and interpretation. Make reasonable attempts to resolve it; where resolution is impossible, record the missingness and documented disposition rather than inserting an invented answer. The authorized sponsor and statistical or clinical reviewers should approve any exception and preserve evidence of the decision. Critical unresolved questions may require postponing lock.

No. Required protocol-specific competence, authorization, and appropriate investigator oversight must be established before carrying out the task.

If permitted by institutional procedures, mark it accurately as a late entry with the actual entry date, author, measurement date or time if reliably known, and explanation. It must not be backdated or portrayed as contemporaneous, and unsupported recollection should not be used to invent precision.

Arrange immediate clinical risk assessment, verify the product and actual dose, and document the exposure, timing, symptoms, and any treatment. Report medication error, overdose, protocol deviation, or adverse event through the channels applicable to the protocol and sponsor; apply seriousness criteria to actual outcomes rather than assuming that every asymptomatic overdose is a serious adverse event.

Respect the participant's decision about the optional activity without treating it as an automatic withdrawal from the main trial. Confirm the scope of the request, stop future optional procedures, and follow the approved consent, protocol, and applicable rules on samples or data already collected. Document the discussion and communicate the change to the relevant study teams so no one continues the optional procedures inadvertently.

Hold protocol-dependent dosing until the required result is available and a qualified investigator or authorized clinician confirms whether dosing criteria are met. Protect participant safety, document the delay and any deviation, and arrange follow-up. Do not dispense on the assumption that yesterday's laboratory results were normal.

Confirm and document the participant's preferred and permitted communication method, then update the applicable contact and reminder systems so confidential information is not sent through the prohibited channels. Check whether mailed contact can still meet time-sensitive safety obligations and arrange a suitable alternative for urgent situations. Share the preference only with personnel who need it; retaining an outdated phone reminder workflow creates an avoidable privacy risk.

Pregnancy exposure itself is not necessarily a serious adverse event, but a congenital anomaly or birth defect is a listed serious outcome under 21 CFR 312.32. Obtain relevant maternal, fetal, and infant information through authorized follow-up, with attention to confidentiality and consent, and have the investigator and sponsor assess timing, possible drug relationship, expectedness, and reporting requirements. Do not assume that every abnormality is drug caused or that an earlier nonserious pregnancy record exhausts the sponsor's safety responsibilities.

No. Pregnancy is not automatically an adverse event or a serious adverse event, but a trial may require prompt pregnancy or exposure reporting and follow-up. The investigator should assess maternal and fetal risks, apply protocol-defined treatment instructions, obtain appropriate consent for additional information, and separately evaluate any adverse pregnancy outcome under the relevant safety definitions.

Obtain the product name, ingredients if known, start date, dose, and use pattern; assess the interaction and ongoing treatment safety with the investigator or qualified clinician. Follow the protocol's prohibited-medication and dose-hold provisions, document concomitant use and any related symptoms, and notify the sponsor as required. Do not remove the medication from the record because it was not prescribed, and do not change trial dosing without appropriate authorization.

After making and recording the reasonable contact attempts specified by the protocol and approved procedures, while respecting privacy and any withdrawal of permission. Record actual attempts and last known status, inform the sponsor as required, and never invent a visit or assume a clinical outcome that was not verified.

Unexpectedness considers the event's nature, specificity, and severity relative to current risk information, not just whether the affected organ is mentioned. Liver failure may be unexpected despite listed mild enzyme abnormalities; seriousness and possible causality must be evaluated separately for required reporting.

Yes. An important medical event may be serious when medical judgment indicates it jeopardized the participant and required intervention to prevent death, hospitalization, or another serious outcome. Classify and report using medical judgment and protocol requirements rather than using admission status as the sole test.

No. Capture and evaluate the event within the protocol-defined follow-up and reporting framework, including required clinical facts, timing, seriousness, and investigator causality assessment. Inform the sponsor through the appropriate channels and follow any endpoint-adjudication procedures. Treatment discontinuation does not itself end obligations to document events required by the protocol.

Escalate the information to the qualified clinician before the scan and follow institutional safety procedures. The investigator should determine whether imaging should proceed, be modified under an authorized option, or be withheld, and whether the protocol deviation needs reporting. Participant safety takes priority over completing an endpoint assessment on schedule.

Assess and document the restored decision-making capacity, then seek the participant's own informed consent for continued research when required by applicable regulations, law, and the IRB-approved plan. Explain past and future activities, the option to decline further participation, and clinically appropriate alternatives. The representative's earlier decision supported enrollment at that time; it does not automatically override the participant's current wishes. Continue necessary clinical care and document any limits on future data or sample collection as applicable.

No. Preserve the original symptom report and timing, plus the later diagnostic evidence and the date it became available. The medically responsible investigator should decide whether the finding represents a refined description of one evolving event or separate events, consistent with the study's reporting rules. Update the event term, seriousness, causality, and outcome through attributable changes and notify the sponsor when required. Deleting early observations may distort the actual clinical course and safety-reporting timeline.

No. A participant's guess is not the same as disclosure of the actual treatment code. Record relevant observations without confirming the allocation, maintain neutral staff behavior, and assess whether side effects may compromise the trial's masking or outcome assessments. Escalate any systematic risk of functional unblinding to the sponsor for evaluation.

Arrange prompt qualified clinical review and follow the protocol's alert, repeat-test, interruption, and notification rules. Record the abnormal result and any associated adverse event without waiting for hospitalization or another seriousness criterion. Determine severity, relatedness, and follow-up needs separately from the question of whether the event is legally serious.

No. Severity describes intensity, whereas seriousness concerns outcomes such as death, immediate life threat, inpatient hospitalization or its prolongation, significant disability, congenital anomaly, or an important medical event requiring intervention to prevent such outcomes. Grade and document severity separately from seriousness.

Withhold study treatment until the investigator evaluates the eligibility error and participant safety, notify the sponsor promptly, and document the actual randomization and reason for ineligibility. Follow the protocol and sponsor's authorized instructions for disposition; do not delete the randomization or silently assign another number.

Record the clinical event and hospitalization faithfully, evaluate it against the protocol's endpoint definition, and determine the serious-adverse-event and sponsor-notification obligations. Medical causality, anticipated disease progression, seriousness, and endpoint classification answer different questions. The investigator should obtain relevant outside records and provide a documented opinion; sponsor aggregate safety review may also be needed. A disease-related explanation does not automatically remove the event from required safety collection, and endpoint recording does not substitute for relevant SAE notification.

No automatic all-or-nothing decision is appropriate. Clarify which procedures the participant declines and which contacts they permit, assess whether the remaining participation is consistent with the protocol and ethical requirements, and involve the investigator in any treatment or safety implications. Respect refusal of the blood draw, document deviations or partial discontinuation when applicable, and continue only the follow-up the participant authorizes and the study can legitimately perform.

Document the report accurately as preliminary, evaluate any immediate safety needs, and seek permissible supporting records or confirmation under the protocol and privacy requirements. Keep the source and verification status clear and route the case through endpoint adjudication when applicable. Neither invent details nor code an unverified event as definitively absent simply because complete hospital documents have not arrived.

Ask about barriers without pressure, explain the remaining procedures and why follow-up matters, and offer protocol-approved scheduling or remote options where available. Document communication and missed assessments; participant support must not become coercion or an unauthorized change in study procedures.

Have the investigator assess immediate interaction risks, participant well-being, and whether continued study treatment remains appropriate. Obtain trustworthy information about the outside medicine, treatment dates, and adverse events; apply the protocol's concurrent-therapy restrictions and notify the sponsor as required. Document the exposure even if it threatens eligibility or analysis. A participant's desire to remain enrolled cannot override a serious safety concern or approved protocol restriction.

No. The device's measurement method, validation, placement, sampling frequency, data processing, and fitness for the protocol-defined endpoint may differ. Assess whether the trial documents permit an alternative device and whether its data are comparable. Preserve the provenance of the device and collection interval, and mark any unsupported readings appropriately. Similar display units do not establish that two digital measures are interchangeable for analysis.

No. The participant's original entries should remain attributable and intact. Any permitted clarification must use a controlled, traceable process that preserves the original content and identifies the author, time, and reason for a change; staff must not replace patient-reported data with their interpretation.

Record the participant's report and the actual tablet count as separate facts, check the dispensing and return history, and ask about missed, lost, or spilled doses without coaching a particular answer. Document and evaluate the discrepancy; do not infer perfect adherence from the interview or fabricate an exact dosing history.

Not without verifying that direct-to-participant supply is permitted by the protocol, applicable rules, and the sponsor's documented process. Evaluate participant identity, authorized delivery location, storage conditions, receipt confirmation, medication counseling, accountability, and a plan for excursions or delivery failure. Coordinate with the investigator and responsible pharmacy or sponsor personnel. A convenience request is not authorization to bypass controlled drug distribution or tracking.

Provide clinically necessary treatment first, document the rescue therapy, and apply prespecified rules for subsequent endpoint collection and analysis. When feasible, keep outcome assessors unaware of the rescue details or use a separate blinded assessor. Record potential masking breaches and do not omit a participant's results simply because rescue treatment was needed.

Secure the returned container, record the actual count and appearance without assumptions, and promptly seek pharmacist and investigator assessment. Review labeled kit and lot history, dispensing records, participant account, and any risk of accidental co-storage or misadministration. Determine whether urgent clinical evaluation, sponsor notification, quality investigation, or protocol-deviation reporting is necessary. Do not discard the mixed tablets, guess their origin, or 'correct' accountability figures merely to balance the ledger.

No. Treatment discontinuation does not automatically terminate endpoint collection or remove later outcomes from the analysis. Record the event and continue permissible protocol-defined follow-up, respecting consent and safety. How the outcome contributes to the analysis depends on the prespecified endpoint, estimand, and statistical plan. Excluding it solely because treatment stopped can introduce bias into the assessment of treatment effect.

No. Distinguish treatment discontinuation from withdrawal of consent for follow-up. If the participant agrees and the protocol permits, continue appropriate safety and outcome collection, record treatment stop date and reason, and respect any limits the participant places on further contact or data collection.

Check whether the date can be established from contemporaneous, reliable source information and the protocol-approved collection system. If it cannot, record it as unknown and follow laboratory and sponsor instructions about usability or repeat collection. Do not invent an approximate date or present an unverified value as a confirmed collection time.

Promptly alert the medically responsible investigator, obtain the participant's account, and seek the outside records through authorized channels. Determine whether the event requires clinical attention, adverse-event documentation, serious-event notification, or additional protocol evaluations. Record what is known and what remains unconfirmed, then update the record when authenticated information arrives. Do not postpone urgent safety action merely because an outside discharge summary is missing.

No. The amount absorbed is uncertain, and an extra dose could cause an unintended exposure. Follow the protocol's vomiting and redosing rules and obtain a medically appropriate decision from the responsible investigator or designated qualified clinician. Document the original dose time, vomiting, symptoms, decision, and any additional medication accurately. If no applicable instruction exists, escalate rather than inventing a replacement-dose rule at the bedside.

Usually not. Preserve the original allocation and audit history, stop any further incorrect actions, and consult the investigator and sponsor/randomization administrator for a documented, authorized plan. Assess participant treatment risk and potential analysis bias; never retrospectively modify stratification records to conceal the error.

Discuss the participant's preference respectfully while assessing whether timing changes would affect drug exposure, fasting requirements, safety tests, or the validity of scheduled outcomes. Determine whether the existing protocol allows an acceptable dosing window or an approved accommodation. Involve the investigator and, when needed, sponsor or IRB before changing procedures. Do not pressure the participant to forgo a religious practice or silently record adjusted times as though doses occurred on schedule.

Honor the request to stop future contact or procedures as far as applicable consent and requirements allow, and clarify the options for further use of specimens or data. Explain accurately that records already collected for regulated trial integrity, safety, or required retention may not be erasable on demand. Avoid promising universal deletion or continued access contrary to the approved consent and law. Document what the participant requests and how each part is addressed.

No. Participation must remain voluntary, without penalty or loss of benefits to which the person is otherwise entitled. Apply the IRB-approved payment terms fairly for activities already completed and explain any conditions that were disclosed prospectively. Do not use withheld payments to coerce continued visits. Document the withdrawal and payment disposition and make sure staff distinguish reimbursement for expenses from incentives for participation.

No. Preserve the event's chronology, including onset, each clinically supported severity change, interventions, and resolution or continuing status. Update the adverse-event record using the trial's conventions and the investigator's assessment, while retaining the prior information and audit trail. Reassess reporting obligations if new seriousness, relatedness, or other reportable features emerge.

No. Follow the protocol and safety-reporting plan for clinically appropriate follow-up, obtain material outcome information when reasonably available and permitted, and keep the sponsor informed of required updates. Establish who will follow the case, how communications will occur after routine site operations cease, and where subsequent information will be stored. Do not pressure the participant to accept unwanted research contact; coordinate ongoing medical care separately. Budget or monitoring-visit completion does not override a participant's safety needs or applicable reporting duties.

Invented or averaged measurements can distort the endpoint and obscure systematic missingness linked to use of the technology. Record the actual gaps, investigate usability and adherence causes, and provide permitted charging support or device replacement. Evaluate missing-data effects according to the prespecified analysis approach and monitor recurrence. Do not present inferred values as though a device observed them; retain original data and metadata that distinguish observed from estimated information.

Arrange prompt clinical assessment of the exposed participant and determine potential toxicity or loss of treatment effect. Stop use of potentially affected preparations, preserve batch and preparation records, and inform the investigator and sponsor through the safety and quality channels. Establish what was actually administered, record any adverse event or protocol deviation, and investigate root cause before resuming preparation. Never alter the medication administration record to reflect the intended formulation instead.

Confirm that the sponsor has authorized the specific alternative disposition, preferably in a traceable written instruction that identifies the products, lots, quantities, site, and method. Follow local pharmaceutical and environmental requirements, use authorized personnel, witness destruction if required, and retain destruction certificates and updated accountability logs. Under 21 CFR 312.59, a sponsor may authorize disposal instead of return only if the alternative does not expose humans to drug-related risks, and the sponsor must maintain written disposition records. A casual verbal assurance is inadequate evidence of final accountability.

Record the true collection time relative to the verified dose time, identify the specimen as postdose rather than predose, and notify the investigator and sponsor or laboratory as required. Assess whether an additional collection is permitted and how the error affects analysis. Never change a clock time or specimen category to match the intended schedule.

Segregate suspect stock and investigate the quantity and tampering discrepancies with the sponsor or authorized supply contact. Document counted, damaged, and usable inventory, preserve shipping evidence, and release only verified acceptable stock according to approved procedures. Do not adjust the receipt count simply to match paperwork.

A normal display from an unqualified instrument is not proof that study product remained within required conditions. Secure potentially affected inventory as appropriate, obtain sensor calibration and backup evidence, assess the period of uncertainty, and ask authorized pharmacy, quality, and sponsor personnel to decide whether product can be released. Identify any doses already dispensed and assess participant impact. Record the investigation and corrective controls without inventing temperature data or assuming that every kit is automatically unusable.

No. Under 21 CFR 312.32(c)(1)(iii), findings from animal or in vitro testing suggesting a significant human risk can require an IND safety report, even with no matching human case. The sponsor should promptly evaluate the finding's relevance, severity, exposure, and implications for the ongoing study. If reportable, the sponsor must notify FDA and participating investigators within the applicable IND safety-reporting timeframe and consider changes to monitoring, consent, dosing, or enrollment to protect participants.

Confirm that the investigator can provide meaningful oversight, make clinical decisions, respond to safety issues, and arrange qualified coverage; a well-staffed coordinator team does not replace the investigator's responsibility.

These are different milestones. The last participant's last visit is an operational participant-contact or assessment event as defined in the study plan; database lock follows the documented processes for data cleaning, reconciliation, and finalization; and the clinical study report integrates trial conduct, analyses, and findings after appropriate data processing. A trial may still have outstanding safety follow-up, external datasets, regulatory submissions, or archiving after its final routine visit. Tracking each milestone separately prevents inaccurate status reporting and supports appropriately timed analysis, disclosure, and retention decisions.

Assess how the revised timepoint affects participants already enrolled, comparability of their measurements with future participants, and the prespecified statistical analysis. Determine whether the change alters trial scientific quality and requires FDA submission and IRB approval under the applicable rules. Plan prospective procedures and documented handling of previously collected outcomes; do not silently relabel week-12 results as week-16 observations.

No. Document the actual visit date and assessments, note the out-of-window deviation, and evaluate any effect on safety or endpoint interpretability. Complete permitted assessments, inform responsible parties according to reporting rules, and use the real dates in source and case report records.

Document the actual intake and timing, then follow the protocol's rules for an invalid fasting condition, postponement, or a repeat collection. Ask the investigator to evaluate any clinical implications. Do not label the sample as fasting or discard the discrepancy simply because the participant traveled far for the visit.

Obtain a workable arrangement covering access, scheduling, qualified readers, blinding procedures, and data transfer before beginning required assessments; assumed departmental cooperation is not a feasibility plan.

Preserve the actual ECG record, determine with the investigator whether a protocol-permitted repeat is possible, and document missing assessments and the reason. Notify the sponsor as required, assess safety and endpoint impact, and do not create or copy nonexistent tracings.

Determine whether the protocol, approved procedures, and assessment method permit a remote alternative that preserves the examination's safety purpose and data interpretability. If not, seek the required sponsor and IRB or regulatory review rather than labeling an unapproved video call as the required examination. Manage any immediate clinical needs separately, document the disruption and actual procedure, and record an out-of-window or missing assessment where appropriate.

Under 21 CFR 312.32(c)(1)(ii), findings from epidemiological, pooled, or other clinical studies can require IND safety reporting when they suggest a significant risk in humans exposed to the drug, whether or not the sponsor conducted the research. Assess study quality, relevance to the product and dose, and the strength of the safety signal rather than rejecting it because it came from an outside source. Determine reportability, communicate promptly where required, and reassess participant protections; not every published association automatically meets the threshold.

Define permissible access and use, confidentiality safeguards, approved outreach methods, retention or return of information, and accountability for the agency's work under applicable privacy and research requirements.

Resolve the logistical limitation with validated transport or local testing arrangements, or reconsider the site's participation; routine deviation from the safety schedule is not an acceptable activation strategy.

Do not mark an incomplete confidential safety interview as fully conducted merely because the video link connected. Confirm identity as required, explain the privacy concern, and seek an appropriate private opportunity to complete the sensitive questions or arrange an approved alternative. Address any immediately apparent clinical risk while limiting unnecessary disclosures. Document which assessments actually occurred, the reason others were deferred, and the resulting follow-up plan.

Because the statements may undermine voluntariness, the IRB may examine consent records, recruitment practices, staff training, and participant accounts. Under 21 CFR 56.109(f), an FDA-regulated IRB has authority to observe, or have a third party observe, consent processes and the research. The institution and investigator should stop coercive statements, protect care access, assess whether prior consent was valid, and report significant noncompliance through applicable channels. Additional training alone is insufficient if the underlying pressure persists.

Arrange prompt clinical assessment by the responsible investigator, create a truthful contemporaneous record, and follow the protocol's safety and injury-reporting processes. Determine whether the event meets serious adverse event or unanticipated-problem criteria and notify the sponsor, IRB, and others within applicable requirements. Explain the appropriate participant contact pathway for care and questions without promising coverage or causation before those facts are established.

An authorized review process should assess whether the project meets the Common Rule definition of human-subject research; it may fall outside that definition if identities cannot readily be ascertained. Check any separate FDA or other applicable requirements.

No. Segregate the bottle, examine objective evidence such as dispensing codes, return dates, and authorized logs, and document any unresolved discrepancy. Ask the sponsor or pharmacist for instructions on reconciliation or disposal; do not guess ownership or retrospectively manufacture a clean inventory trail.

Confirm the revision's receipt, review its new risk information, complete any required investigator or staff training, and provide the current brochure to the IRB/IEC as applicable before affected activities begin.

Site B should continue operating under its currently authorized version while the sponsor and investigator determine what to do about any urgent safety issue. Approval at one site does not automatically authorize the change at another site unless an applicable reviewing IRB arrangement covers both. Track site-specific authorization dates, train staff, and make the transition only after required approvals and sponsor instructions are in place.

Risk assessment should reflect the likelihood of an error, its detectability where relevant, and its potential effect on critical-to-quality factors. A missed safety assessment affecting a treatment decision may deserve urgent attention, whereas a missing nonessential questionnaire may present less risk. Apply proportionate controls based on the consequence of each failure rather than treating every deviation as equally important.

Investigate the new evidence promptly and submit relevant follow-up information as soon as it becomes available, identifying the submission as a follow-up IND safety report under 21 CFR 312.32(d). Retain the original report and trace changes in diagnosis, seriousness, outcome, and causality rather than silently replacing the historical account. Communicate any new participant-protection implications to investigators and update required clinical trial records. A corrected diagnosis may alter assessment but does not justify erasing the initial timely safety notification.

No. Use the protocol-defined measurement, precision, repeat-testing rules, and decision threshold; do not round or selectively choose results to favor continued dosing. Obtain investigator review where interpretation is required, preserve original reports, and document any hold or repeat test. A potentially important safety decision must be traceable to valid data.

Compare the signed or authenticated clinical sources, confirm the event chronology with the investigator, and correct the inaccurate record in each affected system through traceable authorized changes. Reconcile event terms, seriousness, outcome, and relatedness as required. Do not alter data merely to make two reports match if the underlying evidence remains unresolved.

No. IND safety reporting under 21 CFR 312.32 encompasses relevant serious and unexpected suspected adverse reactions from study treatments, including an active comparator when reportability criteria are satisfied. Assess evidence of causation, the comparator's known risk information, seriousness, and the study context. Apply the appropriate blinded-reporting safeguards and notify FDA and participating investigators when required. The sponsor should not assume that only events attributed to its experimental molecule can affect participant protection or an IND safety evaluation.

No. A convened meeting needs a majority of the IRB's members present, including at least one whose primary concerns are nonscientific; for seven members, at least four must attend (21 CFR 56.108(c)).

Under 21 CFR 812.46(c), a terminated significant-risk device investigation cannot resume without both IRB and FDA approval. For a nonsignificant-risk investigation, IRB approval is required, and FDA approval is also required if it was terminated under the unreasonable-risk provision. Evidence of a technical fix alone does not authorize resumed enrollment or device use. Investigators should receive documented authorization and any revised instructions before restarting.

Assess actual visit throughput, staffing, rooms, equipment, and permissible scheduling windows; resolve the bottleneck or revise realistic enrollment projections before site activation.

For research subject to FDA's 21 CFR 56.109(f), the IRB must perform continuing review at intervals appropriate to risk but not less than once per year. Some research under the revised HHS Common Rule may no longer require periodic continuing review, but that distinction cannot simply be imported into an FDA-regulated investigation. Determine which regulations apply and verify active approval and conditions for the site's work. Do not assume an institution-wide policy overrides FDA's IRB requirement.

No. Quarantine expired stock, confirm whether valid replacement supply is available, and contact the sponsor and investigator about an authorized treatment plan and safety monitoring. Track affected kit numbers and account for any missed doses; do not relabel, extend expiry, or use stock without authorized release.

Follow the reviewing IRB/IEC's defined end-of-study reporting process and applicable requirements, with an accurate account of participant disposition, remaining follow-up, relevant problems, and required outcome summaries. ICH E6(R3) section 2.13 recommends that an investigator inform the institution, where applicable, and provide the IRB/IEC with a summary of trial outcomes on completion. Submit required closure documentation, retain the acknowledgments, and distinguish local closure approval from a sponsor's administrative portal access change. Requirements and timing can vary by ethics committee and jurisdiction.

No. Previous site performance does not establish that a newly introduced process or provider is low risk. Assess the provider's qualifications, training, data flow, escalation procedures, and investigator oversight, then adjust monitoring to the importance of the new activities. The revised strategy can use central or remote checks, but it should have a documented rationale and be reassessed after experience accumulates.

Do not disclose restricted unblinded information merely to improve recruitment. Follow the committee charter and statistical access plan, directing authorized recommendations through established sponsor communication procedures. Premature knowledge of between-group outcomes can change enrollment, care, outcome assessment, and trial conduct, undermining reliability. The investigator may receive safety instructions or approved aggregate information without accessing confidential treatment comparisons.

Identify the feasibility gap and obtain appropriate access to equipment or resolve the issue through approved study changes; do not begin affected procedures without the required capability.

Closure should rest on documented assessment of participant impact, completion of required notifications, correction of immediate deficiencies, and evidence that suitable corrective or preventive actions are functioning. If investigation or safeguards remain incomplete, leave the issue open with an owner and escalation path. Report to the sponsor, IRB, or other bodies when their applicable thresholds are met. A reporting period or a changed tracker status cannot substitute for verified resolution.

Predictability undermines allocation concealment and may allow conscious or unconscious selection of who enters each treatment group, introducing selection bias. Stop using the revealing display, alert the sponsor's randomization administrator, assess any affected assignments, and implement an approved controlled correction. Preserve the original allocation history rather than regenerating it secretly.

Follow the approved data-sharing plan: limit transferred fields to what the recipient is authorized to receive, use coded study identifiers where possible, and transmit information through a suitably protected, access-controlled channel. Confirm applicable consent, privacy law, and institutional requirements. Do not treat removing names alone as sufficient when other fields could identify individuals.

Route the notice promptly to the investigator and relevant clinical staff, document review and any required changes to participant care, and identify whether the IRB must be informed or participant communications modified. Check that the portal workflow actually reaches responsible decision-makers and has backup coverage. Filing a safety letter without ensuring its clinical implications are acted on is inadequate.

Keep the suspected event documented, obtain available authorized source evidence, and request clarification or missing imaging according to the adjudication charter. Apply prespecified definitions and record the final determination and reasons. Do not automatically mark the endpoint absent because a document is missing or presume it confirmed based only on the site's initial label.

Confirm the actual device identity using implant labels, operative records, supply logs, and manufacturer or sponsor tracking before correcting the traceable record. Assess participant and recall implications, document who made the correction and why, and notify the sponsor of a potentially material tracking error.

Review whether participants had adequate time and opportunity to understand the study and ask questions, whether signatures and procedures were correctly sequenced, and whether system timestamps are accurate. Examine a sample of contemporaneous records and discuss workflow with the investigator. The pattern is a signal for investigation, not proof that every consent was invalid or that short duration alone violates a fixed federal minimum.

Use a validated or otherwise verified conversion method with the correct analyte-specific factor and preserve the original value, unit, date, and source. Apply the protocol-specified laboratory reference ranges and decision thresholds in the proper units. Resolve any mapping errors before using values to determine eligibility, dosing, or a safety action.

Identify the affected participants, versions, and time window; protect any locally retained original entries; and assess whether the failure created missing or delayed critical data. Coordinate a tested technical correction and an approved alternative capture method where feasible. Document the actual timing and source of each response rather than retrospectively assigning scheduled dates. Review the potential effect on study endpoints and adjust monitoring or participant instructions accordingly.

Request an authenticated source record or other valid corroborating evidence through approved channels. If the result cannot be verified, document the limitation and the investigator's assessment rather than creating a replacement report from memory. The sponsor should determine whether the unverified datum can be used for a safety decision or analysis and whether the gap represents a recurring process defect. Maintain an audit trail for any correction, and do not treat a typed eCRF number as independent proof of measurement.

Under 21 CFR 312.30(c), the sponsor submits a protocol amendment identifying the new investigator, qualifications, and the applicable study; FDA must be notified within 30 days after that investigator is added. This is different from waiting 30 days before the investigator may participate. The site must still have the necessary IRB approval, investigator agreement, training, facilities, and other study-specific authorizations before research activities proceed. Document the effective dates and do not mistake an IND filing for local ethics approval.

No. The investigator must adhere to current approved eligibility criteria; a sponsor's informal permission is not a substitute for required protocol changes or regulatory/IRB review. Protect the candidate, document the assessment, and use an authorized amendment or exception process if one legitimately applies.

Yes. Under 21 CFR 812.150(b)(6), the sponsor must notify FDA and all reviewing IRBs of the request within 30 working days after making it and state the reason. The site should also follow the sponsor's authorized instructions and maintain accurate receipt, use, repair, return, or disposal records. Where patient safety is at risk, appropriate clinical actions should occur promptly; the 30-working-day notice deadline is not permission to delay protective measures.

Determine whether the memo merely explains existing approved wording or actually changes who may enroll. A substantive new exclusion criterion should follow applicable sponsor change control, FDA IND-amendment requirements when triggered, and IRB review before use, except for an applicable immediate-hazard exception. A document label does not make an unapproved eligibility change permissible. Preserve the decision and the version sites were instructed to follow.

Identify risks to trial-specific critical-to-quality factors, assess their likely impact, and design proportionate prevention and detection measures rather than adding controls indiscriminately.

Under 21 CFR 812.150(b)(7), the sponsor must notify FDA within 30 working days of completion or termination and submit a final report within six months to FDA, all reviewing IRBs, and participating investigators. These are two distinct steps with different clocks and recipients. Confirm the completion or termination date, retain delivery evidence, and coordinate the scientific and safety content of the final report. The six-month report deadline does not excuse missing the earlier notification. These requirements concern significant-risk device investigations; the rule for non-significant-risk devices differs.

Restrict the revealing field immediately, determine who viewed it and when, and evaluate how the exposure might influence clinical decisions, endpoints, or behavior. Preserve access logs and seek sponsor statistical and quality input on any integrity consequences. Protect the blind for unaffected personnel and apply a documented remediation plan; reblinding exposed individuals may not erase the bias. A data view can compromise trial masking even without displaying a field explicitly labeled with treatment assignment.

Under 21 CFR 312.56(d), the sponsor must discontinue the investigations presenting that risk as soon as possible, and no later than five working days after deciding they should be discontinued. It must notify FDA, all relevant IRBs, and investigators who participated, ensure appropriate disposition of outstanding drug stock, and furnish FDA a full report of its actions. Urgent participant protection should begin immediately.

The sponsor must promptly secure compliance or discontinue investigational-drug shipments and end that investigator's participation. If participation is ended, the sponsor requires return or disposal of the investigational drug under the applicable rule and notifies FDA. The sponsor should also protect enrolled participants and document the decisions. An open corrective-action plan cannot substitute indefinitely for addressing persistent noncompliance.

For a covered study, sponsor payments supporting the investigator's activities with a value above $25,000, excluding study-conduct costs, meet the definition if made during the study or within one year afterward.

Promptly investigate the new information and record when the sponsor determined that the event met the applicable IND reporting criteria. Under 21 CFR 312.32(d)(3), an event initially deemed nonreportable that is subsequently found reportable must be submitted as soon as possible, no later than 15 calendar days after the new determination, subject to any more stringent applicable provision. Preserve the original assessment, the new evidence, and the reasoning for reclassification. Do not backdate the determination or erase the earlier conclusion.

No. The site must obtain documented authorization and controlled instructions supporting any relabeling or expiry extension, including product, lot, new date, and who is qualified to perform the task. Verify that the stability evidence and applicable requirements support use, and reconcile the affected stock and labels. Maintain the original and revised records so investigators can establish which kits were eligible for dispensing. A general sponsor email or handwritten correction without an approved process is not sufficient control.

A complete set of final values is not enough if regulated record provenance, prior modifications, and signatures cannot be reconstructed or accessed. Assess which original records and metadata must be retained, validate the migration and reconciliation, and preserve a readable, inspectable historical record in the legacy system or a suitable controlled archive. Document data mappings, failed items, and remediation. Do not deactivate the former platform until essential trial records can be retrieved with integrity for authorized review.

Immediately identify and segregate affected devices, stop their use as directed, reconcile serial or lot numbers with participant exposures, and arrange clinical follow-up when needed. Document the sponsor's instructions, communication, disposition, and any reporting obligations; a recalled unit must not remain available for routine use.

Neither categorization should be assumed. Under 21 CFR 312.31(a)(2), a report about discontinuance of a clinical investigation can be handled through an IND information amendment when it is essential information outside the scope of other required submissions. Confirm whether any safety finding also triggers separate urgent duties, and notify relevant investigators, IRBs, participants, and authorities as applicable. Document the reason, participant care plan, investigational-drug disposition, and status of the other active protocol without prematurely closing the entire IND.

No. Under 21 CFR 812.35, changes generally require a supplemental IDE approval and appropriate IRB approval unless they meet a specified exception, such as qualifying developmental changes supported by credible information with notice to FDA within 5 working days. Assess whether the change affects device design, basic operation, risk, participant welfare, or data validity. Document the regulatory pathway before distribution; do not assume a software change is always minor.

An increase in dose that significantly affects participant safety requires a sponsor protocol amendment submitted to FDA under 21 CFR 312.30 and approval from the responsible IRB before routine implementation. The site must also use the authorized protocol, update relevant consent and training as necessary, and verify that the proposed dose is clinically appropriate. FDA submission alone does not replace IRB approval.

Device accountability must remain reconstructable. For an IDE study, 21 CFR 812.140 requires records of device type and quantity, receipt, use, repair, return, and other disposition, including identifying codes and the persons involved, as applicable. Reconcile each unit against shipment and site records, document discrepancies, and link repairs to the correct device and participant exposure histories. A box count or courier receipt alone does not establish which specific units were returned or whether all participants' device histories can be reconstructed.

For an applicable clinical trial subject to 42 CFR 11.42, the standard rule in 42 CFR 11.44(a) requires results information no later than one year after the primary completion date, not automatically one year after the overall study completion date. Specific delayed-submission certifications, granted extensions and provisions for secondary-outcome or additional adverse-event data can alter the timing. Verify the study's legal applicability and any approved exception before making deadline commitments. A pending secondary endpoint does not, on its own, postpone all required primary-results reporting.

Promptly inform participants as appropriate, ensure suitable treatment transition and follow-up, and follow the approved early-termination and safety procedures. The investigator and sponsor should communicate the reason for stopping to the IRB/IEC and authorities as required, and document when each participant was notified and what care or monitoring was offered. ICH E6(R3) sections 2.6 and 3.17.1 address premature termination or suspension. A decision that a trial lacks efficacy does not cancel duties to manage emerging adverse events, protect confidential information, or preserve reliable study records.

Not as a blanket rule. ICH E6(R3) section 3.17.2 calls for appropriate trial reports whether a trial is completed as planned or prematurely terminated, with provision to regulators as applicable. The report should describe enrollment achieved, exposure, available efficacy and safety data, reasons for termination, important deviations, and the statistical limitations caused by the smaller sample. The exact format and submission requirement depend on the jurisdiction and trial circumstances. An inconclusive result does not justify erasing what participants contributed or concealing why the study ended.

A secure, computer-generated, time-stamped history of the entry and change, including when it occurred, without obscuring the previous information (21 CFR 11.10(e)).

A publicly traded equity interest exceeding $50,000 during the study or the following year meets the definition of a significant equity interest in the sponsor and must be assessed for the required FDA disclosure.

When appropriate, state that significant new findings arising during the study that may affect the participant's willingness to continue will be provided to the participant (21 CFR 50.25(b)(5)).

The consent information should explain that the treatment or procedure may involve presently unforeseeable risks to the participant or, if relevant, to an embryo or fetus.

No. Partial identifiers do not prove that the records concern the same person, and a mistaken merge could expose private data or corrupt randomized outcomes. Ask authorized site staff to compare legitimate source identifiers under approved privacy controls, determine whether true duplicate enrollment or a coding issue exists, and document the verified conclusion. If duplicate participation is confirmed, notify the sponsor and investigator for clinical, protocol, and analysis decisions. Retain the original records and a traceable correction rather than collapsing them by inference.

Assess whether any participant received an unsafe or incorrect dose, provide necessary care, and stop use of the obsolete instructions. Document affected cases, notify sponsor/IRB as required, retrain and verify staff access to the approved version, and evaluate whether broader process failures require CAPA.

Determine whether the workflow was authorized and secure, protect identifiable images, and make sure required original files, metadata, and participant associations are preserved in the approved source system. Investigate potential unauthorized storage or transfer and follow privacy-incident reporting requirements when applicable. Arrange removal from uncontrolled locations in accordance with policy after retention is assured, and train staff on approved capture methods. Merely uploading a copy does not resolve source authenticity or confidentiality concerns.

No. Publication and structured results submission are separate obligations. For covered applicable clinical trials, the responsible party must submit the required results data elements through ClinicalTrials.gov within the applicable statutory and regulatory deadlines, including permitted corrections and updates. A published manuscript can support scientific transparency but is not a replacement for the registry's required results information. Verify the public record, required outcome and adverse-event fields, submission status, and any quality-control notices, and preserve evidence that registry obligations were completed.

Segregate the affected supply, document the excursion, notify the sponsor or responsible pharmacy, and avoid dispensing it until authorized disposition is documented.

Confirm the requester's identity, authorization, scope of access, purpose, and secure transfer method through established sponsor or institutional contacts. Check the governing agreements, ethics and consent limitations, and whether the proposed dataset is genuinely de-identified under applicable requirements. Maintain a record of what is supplied and to whom. The absence of direct participant names does not itself justify sharing research data with an unverified outside party; legitimate inspections and audits still require appropriate handling and traceability.

Location tracking can create a new privacy risk and change what participants are asked to contribute. Before implementing it, assess whether the protocol, privacy disclosures, consent documents, data controls, and IRB approval must change, and whether existing participants need renewed informed consent. Identify who can access the data, its purpose, retention, and any alternatives. Technical ability to activate the feature does not itself authorize new research data collection, even when other study procedures remain unchanged.

Review concomitant-research restrictions, competing interventions, relevant washout periods, cumulative risk, and potential interference with outcomes. The investigator should document eligibility and any necessary coordination; participation in another study is not automatically prohibited unless requirements or clinical judgment make it unsuitable.

A key risk indicator is a measure used to detect an emerging operational risk and prompt proportionate action, often at a site or process level. A quality tolerance limit is a prespecified acceptable range for a critical trial-level parameter. Exceeding that limit should trigger an evaluation of possible systemic impact and whether corrective action is needed. Neither metric replaces clinical judgment or the obligation to protect participants.

Not necessarily. Inpatient hospitalization is a seriousness criterion when it results from an adverse event, but planned admission for a preexisting condition without deterioration is not automatically a new adverse event. Review the original indication, any intervening complication, timing, the protocol's safety definitions, and investigator medical judgment. If an untoward event or complication occurs, document and classify it appropriately. Never conceal a qualifying event by calling all hospital care 'elective,' and do not equate every hospital stay with a reportable reaction.

Establish which protocol activities occur there, who supervises them, whether personnel and facilities are qualified, how source records and safety reports flow, and which approvals apply to that location.

Apply the protocol's pause or stopping rule immediately and withhold affected study activities until qualified personnel complete the specified safety review and any required authorization to restart. Notify the sponsor and oversight bodies as applicable, document the triggering data and decisions, and continue appropriate participant care and follow-up. Enrollment pressure cannot waive a stopping rule.

The primary completion date is ordinarily the trigger: the date the final participant is examined or receives an intervention for final collection of data for the primary outcome, not the date of the last secondary follow-up or a subsequent database lock. Under 42 CFR 11.44(a), results information for covered applicable clinical trials is generally due within one year of primary completion, subject to specified exceptions, certifications, or extensions. Verify the study's actual dates and responsible-party obligations; incomplete secondary outcomes may have their own later submission deadlines under section 11.44(d).

For applicable trials initiated on or after January 18, 2017, 42 CFR 11.64(a)(1)(ii) generally requires updating the actual primary completion date, with actual enrollment, within 30 calendar days after that milestone. The actual study completion date must also be updated within 30 calendar days after it occurs. The responsible party should confirm additional status, contact and verification updates as relevant, and maintain an accurate record. Do not wait until a journal publication or final clinical study report to correct registry dates. Distinguish record updates from the separate results-posting deadline.

The investigator must submit a final report to the sponsor and the reviewing IRB within three months after the investigation or the investigator's part is terminated or completed. The relevant clock starts from the applicable completion or termination milestone, so a site may owe its report before the entire multicenter trial ends. Prepare a complete and accurate account of participation, device use, outcomes and important safety or protocol issues. Document submission dates and acknowledgments. Do not confuse this investigator deadline with the separate final-report obligations imposed on an IDE sponsor.

No. Under 21 CFR 312.64(c), an IND investigator must provide the sponsor with an adequate report shortly after completing participation, but that paragraph does not specify a universal three-month deadline. The sponsor needs sufficient accurate information to evaluate the investigation and fulfill regulatory responsibilities. A device investigator covered by 21 CFR 812.150(a)(6), by contrast, has an explicit three-month final-report requirement to the sponsor and reviewing IRB. Check which regulatory framework applies and any stricter protocol, contract, or institutional deadlines.

Under 21 CFR 312.38, the sponsor may withdraw an effective IND, but must notify FDA, end all clinical investigations conducted under that IND, notify current investigators, and arrange return or authorized disposition of all investigational-drug stocks under section 312.59. If the withdrawal is for safety reasons, the sponsor must promptly tell FDA, investigators, and reviewing IRBs the reasons. Coordinate orderly participant treatment and follow-up and preserve required records. Ending a single protocol is not necessarily the same act as withdrawing the entire IND.

Sponsor retention has its own wording and triggers: under 21 CFR 312.57(c), required sponsor records and reports are kept for two years after a marketing application is approved for the drug, or, if an application is not approved, until two years after investigational shipment and delivery are discontinued and FDA has been notified. This is not identical to the indication-specific investigator rule in section 312.62(c). Document the regulatory basis for the proposed destruction date, assess other applicable retention obligations and legal holds, and communicate clear instructions to archive custodians before any records are released.

Do not send controlled substances through an unauthorized return method. Verify the drug's legal schedule, the site's registration and custody requirements, sponsor directions, and applicable DEA, state, carrier, and institutional rules for shipment, transfer, or destruction. Maintain secure storage until an authorized disposition is completed and document the witnesses, quantities, dates, and receiving party as applicable. Closeout accountability must satisfy both IND rules and controlled-substance laws; a sponsor instruction does not remove additional legal requirements.

The sponsor must be able to demonstrate that critical derived data are reliable and traceable. Confirm that the scoring algorithm and version are controlled, its implementation has been tested, input-output relationships can be checked, and appropriate records are accessible for monitoring, audit, and inspection. Confidential business terms may be managed contractually but should not prevent meaningful oversight of critical trial data.

An apparently intact database does not establish who created, modified, or deleted records during the gap. Determine which regulated records and critical fields were affected, whether trustworthy alternate records exist, and whether Part 11 and protocol requirements were met. Preserve system-change evidence, notify responsible quality staff, assess participant and data-integrity risk, and implement an appropriately tested corrective plan. Do not invent reconstructed audit events or assert that no data changed without evidence.

Follow the prespecified clinical escalation pathway and promptly involve the responsible clinician or qualified safety team to determine whether assessment is required. Technical verification is useful, but an unconfirmed artifact assumption must not delay appropriate care. Preserve the original alert, device-quality information, timestamps, review decision, and any follow-up. Separate clinical safety triage from later decisions about whether the signal qualifies as an endpoint or analyzable measurement.

No. Investigate whether trustworthy provenance can be restored from authenticated source systems, participant-device assignment histories, and retained metadata. Quarantine affected data from unverified analysis while assessing the scope, potential misattribution, participant impact, and any reportable quality issue. Document validated recovery steps or explicitly flag irrecoverable uncertainty. Assigning identities based on memory or assumed upload sequence could create false trial results, even when numerical readings look plausible.

A documented response should identify affected participants, assess clinical and data impact, address the root cause, assign corrective actions and due dates, and provide evidence that staff follow the revised process. The monitor or sponsor should verify effectiveness; a promise to 'be more careful' is not sufficient closure.

A simultaneous cross-site change suggests that new field logic, instructions, validation rules, or data transfers may be causing problems. Examine the release and change-control records, test the form and edit checks, and assess critical data affected. Communicate any correction and preserve the audit history. Correcting a shared system defect may be more effective than retraining each site for an error introduced centrally.

Not until the loss is assessed. Determine whether records, metadata, signatures, or audit events were omitted; involve system owners and quality personnel, validate the restore against reliable backups, and document the impact and remediation. Protect participant safety and key decisions while integrity is uncertain. A visible data table alone does not prove the regulated record is complete.

Not merely because the person is a relative. Determine whether the participant has decision-making capacity for this decision, whether the protocol and IRB-approved materials permit the procedure, and whether an appropriately recognized legally authorized representative can provide permission under applicable law. Follow any requirements for participant assent or objection and prioritize clinical safety. Document who made the decision, their authority, and what information was provided.

Check the approved communications plan and applicable disclosure requirements, then provide or arrange an accurate, understandable, non-promotional summary when available. Explain uncertainty and limitations rather than implying that a group-level result proves the participant personally benefited. Protect other participants' confidentiality and coordinate disclosure of individual treatment assignments only through authorized procedures. ICH E6(R3) section 3.17.2(c) supports making finalized results publicly available, informing investigators of treatment assignments in blinded trials, and using lay language for results shared with participants. Document the communication as required.

Maintain the planned blind until authorized analysis and adjudication steps are complete, unless a participant-specific safety need or approved procedure warrants earlier unblinding. Premature release can bias endpoint classification, data reconciliation, or interpretation. Arrange controlled access, document any permitted unblinding, and verify who may receive allocation information and when. ICH E6(R3) section 3.17.2(c) contemplates providing investigators with participant treatment information after unblinding and finalization of relevant analyses, subject to regulatory requirements. Closure of visits is not itself a reason to disclose randomization codes.

No. Evaluate whether the error affects participant safety, endpoint classification, regulatory reporting, or analysis. Follow the sponsor's documented post-lock correction and change-control process, with authorized approval, an explanation, audit trail, assessment of downstream datasets and analyses, and controlled re-lock if necessary. Preserve the previous locked version and a record of changes and sign-offs. ICH E6(R3) data-governance principles require traceable finalization and justified corrections, not a guarantee that mistakes can never be corrected.

No. Assess whether the new facilities support safe protocol conduct, whether the change affects consent, confidentiality, investigational-product handling, and access to source records, and whether sponsor, IRB, contract, or regulatory notifications are required. Update controlled site information and train staff before using the location. The obligations depend on the nature of the move, rather than a universal rule that every address change needs the same FDA submission.

No. An adverse event of special interest, or AESI, is selected for targeted monitoring because it is important to the product or mechanism; it need not be serious under the regulatory definition. Record its actual grade, seriousness, onset, and clinical findings, then follow the protocol-specific expedited collection, testing, and sponsor-reporting rules for that AESI. Do not misclassify it as an SAE solely to trigger notification, and do not skip AESI reporting because the participant was not hospitalized.

Confirm protocol and IRB authorization, the scientific and safety justification, whether updated participant information or consent is required, and whether personnel and equipment are ready. Identify which participants and timepoints are affected. A participant's consent to the original protocol does not by itself authorize newly added procedures; give individuals the opportunity to make an informed decision under the approved process.

For trials subject to the specified registration-update provisions, the responsible party must update Overall Recruitment Status no later than 30 calendar days after the change. When status becomes 'suspended,' 'terminated,' or 'withdrawn,' it must also submit the Why Study Stopped information. The registry change does not replace communication with investigators, IRBs, participants, or regulators when separately required.

No. Review role, time zone, scheduling, edit reasons, supporting source records, and user access logs before drawing conclusions. Investigate discrepancies through a documented, fair process that preserves audit-trail evidence and separates legitimate delayed entry from unauthorized manipulation. Escalate substantiated integrity concerns and implement corrective controls.

Supply authentic temperature records and all available service, alarm, calibration, and maintenance documentation, identifying what is missing. Assess potential impact on stored samples or products, investigate the recordkeeping failure, and record appropriate corrective action. Do not manufacture historical maintenance entries or claim that routine temperature summaries prove maintenance occurred.

Assess the participant's needs and ability to provide the required information; consider accessible technology or assistance explicitly allowed by the instrument, protocol, and approved procedures. Determine whether help from another person would turn a direct patient report into a proxy report. Document the method and any change in data collection, maintain participant autonomy, and obtain necessary approvals before altering how a critical endpoint is measured.

The data flow from diary to database, including transfer completeness, timestamps, identification, permissions, error handling, and reconciliation, so required patient-reported data are attributable and usable.

Determine whether the export preserves the essential records' complete content, provenance, required metadata, approvals, signatures, relevant audit trails, and links needed to interpret them. Validate readability, searchability, access controls, and retrieval over the required retention period. Arrange an alternate archive or export method if material record attributes would be lost, and document qualification or verification of the migration. ICH E6(R3) Appendix C expects essential records to remain complete, readable, readily available, and traceable after archival; a PDF folder by itself may not meet those needs.

Preserve both the raw input and the specific validated or verified algorithm version used to calculate each result. Determine whether the protocol or statistical analysis plan specifies an algorithm, evaluate the change's effect on comparability and bias, and implement a controlled solution with sponsor scientific and quality oversight. Any justified reprocessing should be reproducible, versioned, and reflected in the audit trail. Do not choose whichever output makes the treatment appear more effective or silently replace all earlier scores.

Not unless the approved instrument and protocol specifically permit proxy reporting. A patient-reported outcome is intended to come directly from the participant without interpretation by another person. Staff may document the spouse's observations as caregiver-reported information, where permitted, and assess an approved accessibility accommodation. They should not silently relabel a proxy account as a self-report, because the change can alter the meaning of the endpoint.

No. An expedited reviewer may exercise other IRB authorities but cannot disapprove research. Disapproval requires the nonexpedited, convened-board procedure (21 CFR 56.110(b)).

Ensure continued availability, integrity, and traceability of the original results and relevant metadata, clarify who will retain essential records, and secure authorized access for ongoing evaluation, audit, and inspection. Document transfer methods and reconciliation and confirm no participant-safety reporting is interrupted. Ending a commercial contract does not end the responsible parties' obligations concerning trial data and records.

No. Form FDA 483 documents the investigator's inspectional observations and is not itself a final FDA compliance determination. The organization should assess each observation, preserve relevant evidence, and provide a timely, substantive response with investigation, corrective or preventive actions, owners, and effectiveness measures. Subsequent FDA actions depend on the agency's assessment.

Explain the outage accurately, involve authorized IT and compliance staff, and provide secure, accurate and complete records through available validated backup or retrieval mechanisms where feasible. Record requests, delays, and follow-up delivery while preserving audit trails and confidentiality controls. Do not create substitute records or restrict lawful inspection access merely because the preferred interface is down.

The IRB must use written procedures under 21 CFR 56.108(b) for prompt reporting of serious or continuing noncompliance, unanticipated problems involving risks, and suspensions or terminations of IRB approval to the IRB, appropriate institutional officials, and FDA. The investigator and institution should address participant safety and halt unauthorized activities while the events are evaluated. Do not assume that reporting only to the sponsor or adding staff training satisfies the IRB's distinct regulatory process. Document the seriousness determination and required notifications.

Under 21 CFR 812.150(a)(5), the investigator must report the use to the sponsor and reviewing IRB within 5 working days. Under 21 CFR 812.150(b)(8), the sponsor must submit a copy of that report to FDA within 5 working days after receiving it. An exception must actually satisfy the governing consent regulations and required documentation; a good clinical outcome does not retroactively make an unsupported omission of consent permissible.

The investigator or sponsor may transfer required records to another person who accepts responsibility for maintaining them and meeting inspection obligations, but FDA must receive notice of the transfer no later than 10 working days after it occurs. Record the identity of the new custodian, effective transfer date, scope of materials, and arrangements for retention and access under section 812.145. A contractor's physical storage service is not necessarily a regulatory custody transfer; assess the legal relationship rather than sending an inaccurate notice.

Under 21 CFR 312.62(c), required investigator records are retained for two years after approval of a marketing application for the drug for the indication being investigated, or, if no such application is to be filed or approved, until two years after the investigation is discontinued and FDA has been notified. The last participant visit alone does not establish the release date. Obtain sponsor instructions about regulatory status and compare any longer institutional, contractual, or other legal retention period. Keep records complete and accessible until all applicable obligations are satisfied.

Under 21 CFR 312.52, transferred IND sponsor obligations must be described in writing. Where only specified duties are transferred, an obligation omitted from the written description is treated as not transferred; a CRO that assumes an obligation is itself subject to the applicable regulatory duties. Therefore a verbal request does not establish an effective formal transfer of safety-reporting responsibility. Correct the written allocation, ensure uninterrupted reporting and oversight, and verify that responsible personnel understand who performs each task.

No. Section 312.32(c)(1)(iv) requires reporting a clinically important increase in the rate of a serious suspected adverse reaction over the rate listed in the protocol or Investigator's Brochure. This is distinct from the pathway for a newly unexpected single case. The sponsor should verify ascertainment and denominator quality, evaluate the rate increase and seriousness, submit an IND safety report if criteria are met, and consider additional risk controls and updated information for investigators and participants.

Yes. Under 21 CFR 312.64(b), the investigator immediately reports serious adverse events to the sponsor regardless of suspected drug relationship, with an assessment of causality. Provide available clinical details promptly and follow up when additional information arrives, even if the initial cause appears unrelated.

Hold dispensing while the investigator or authorized pharmacy staff reconciles the randomization record, assigned kit, and participant identity with the controlled allocation system. Supply only the authorized allocation, document the discrepancy and any deviation, and involve the sponsor's randomization support according to the approved procedure; do not choose a kit by convenience.

No single site investigator should make that declaration based on confidential interim statistics. The designated independent review body, sponsor, and other responsible parties should evaluate the finding under the charter, statistical plan, participant-safety requirements, and applicable regulatory and IRB obligations. Recommendations must be translated into documented decisions and site instructions. A statistical boundary is part of a decision framework, not automatic marketing authorization or proof of benefit.

No. Roles may be delegated, but the sponsor retains appropriate oversight of sponsor trial activities and the investigator remains responsible for the conduct and records under the investigator's control. Identify the accountable parties, assess missing data and participant effects, coordinate a documented remediation and data reconciliation, and verify that the correction works.

Maintain traceability from the original device and participant exposure through removal, repair, component changes, functional verification, new identifier, and return to service. Confirm sponsor authorization and whether the modification requires regulatory or IRB assessment before use. Record which participants received or were assessed using the changed unit, especially if device performance affects safety or primary endpoints. Do not present a repaired device as the unchanged original without the service history; gaps could conceal failures or invalidate endpoint interpretation.

Under 21 CFR 312.69, an investigator using an investigational drug subject to the Controlled Substances Act must take adequate precautions to prevent theft or diversion, including secure storage with limited access. Maintain dispensing and return records and comply with any applicable controlled-substance requirements and study procedures. Investigate discrepancies or unexplained access promptly, protect participants from compromised supply, and communicate potential diversion through appropriate channels. Ordinary kit counts alone do not establish the required security or control.

Escalate immediately to the investigator and sponsor's medical contact to establish an ethically and clinically appropriate transition plan consistent with the protocol, consent, applicable regulations, and local standards of care. Discuss required tapering, safety monitoring, referral, and access to available standard treatment rather than promising continued investigational supply without authorization. Document counseling and the participant's decisions while protecting voluntary participation. ICH E6(R3) emphasizes suitable therapy and follow-up when a trial ends prematurely. Administrative closeout targets must not override participant safety.

Under 21 CFR 812.150(a)(1), the investigator reports to the sponsor and reviewing IRB as soon as possible, and no later than 10 working days after first learning of the effect. A qualifying effect involves an unanticipated serious device-associated harm or other serious unanticipated issue described in 21 CFR 812.3(s).

Protect the participant, evaluate the cause of the interruption, and establish the documented amount and duration actually delivered from reliable pump and administration records. Ask the qualified investigator or clinician to apply protocol instructions for interruptions, dose completion, and safety monitoring; do not assume the remaining volume equals the amount not received. Record equipment performance, clinical findings, corrective steps, and any protocol deviation or product complaint requiring follow-up.

Yes. Under 21 CFR 54.4(b), relevant financial changes must be promptly reported to the sponsor during the investigation and for one year after the study's completion.

Identify the reporting duties in regulations, the approved protocol, the IRB's written procedures, and documented agreements, then ensure timely communication rather than allowing a responsibility gap. Under 21 CFR 312.66 the investigator must promptly report changes and unanticipated problems involving risks to subjects or others to the IRB; sponsors have separate safety communication and reporting obligations. Document who submitted what and when.

Retain the original signed state, the later attributable correction, and the audit history connecting both to the applicable record. Assess whether the investigator's prior sign-off still attests to the final data and obtain renewed review or signature when required by the system's controls and study procedures. A signature is not blanket approval of any later edits. Do not backdate attestation or suppress a correction to preserve the appearance of prior approval.

The investigator needs sufficient information to determine that activities conducted under investigator responsibility are performed competently and safely, with defined records, clinical escalation, and oversight. A sponsor-arranged provider does not remove the investigator's ultimate responsibility for delegated investigator tasks. Examine qualifications, participant location issues, data access, and whether agreements or regulatory approvals need updating.

ICH E6(R3) calls for the sponsor to have medical personnel readily available to advise on trial-related medical questions or problems. Appropriate coverage, backup contacts, and escalation pathways should be established and communicated to sites, including out-of-hours arrangements where the trial creates that need. The investigator remains responsible for the participant's immediate medical care and should not delay necessary safety decisions while waiting for sponsor advice.

A patent is a proprietary interest in the tested product under 21 CFR 54.2(c); covered-study disclosure considers it separately from sponsor equity and outcome-dependent compensation.

No. That definition requires prospective assignment of human subjects to an intervention to evaluate a biomedical or behavioral health-related outcome. An observational study may still be human-subject research requiring an applicable determination or review.

Identify the institution or person responsible for continuing retention, establish written custody and access arrangements, inventory the essential records and their locations, and verify confidentiality, searchability, traceability, and ability to respond to audits or regulatory inspections. Notify the sponsor of the archive custodian and applicable contact changes. ICH E6(R3) section 2.12.13 expects the investigator/institution to keep the sponsor informed about the person maintaining records when the investigator leaves or the site closes. Additional FDA-specific transfer notices may be required for IDE records. An untracked handover is not an acceptable retention plan.

Before access ends, identify which sponsor-generated letters and other materials constitute essential investigator records and make authorized, complete, durable copies or another assured long-term access arrangement. Preserve dates, versions, acknowledgment history and the ability to search or retrieve them. ICH E6(R3) Appendix C.2.8 specifically notes that investigator/institution records obtained through a sponsor portal may need to be retained by the investigator at trial end. A broken URL is not the same as an archived safety communication. Respect confidentiality and blinding constraints when exporting.

No. They govern different record holders and triggers. Under 21 CFR 56.115(b), an IRB or institution responsible for IRB records must keep the required IRB documentation at least three years after completion of the research. An IND investigator's required case histories and other records follow the distinct section 312.62(c) regulatory triggers. Some institutions retain common documents under an even longer schedule. Identify whose records are being discussed, apply the correct rule to each, and preserve inspection access rather than assuming one universal 'clinical trial retention period.'

Apply the IRB's written determination precisely: stop new screening or enrollment activities covered by the restriction, while conducting only permitted follow-up and medically necessary care. Clarify ambiguous language with the IRB and sponsor rather than treating restricted approval as either unlimited permission or a blanket ban on all participant contact. Update scheduling, recruitment tools, personnel instructions, and investigational-product access as needed. Document the effective date, participant impact, corrective work, and the formal basis for any later resumption of enrollment.

No. Under 21 CFR 56.108(a)(2) and 56.109(f), the IRB may determine that risk warrants more frequent continuing review or independent verification that no material changes occurred. Provide requested safety, deviation, enrollment, and other relevant information promptly. The review schedule is not a guarantee that scrutiny occurs only annually. The investigator and sponsor must also address clinically significant risks immediately through their separate regulatory and protocol obligations, without waiting for a scheduled review cycle.

No. Specialists invited to advise on complex issues may provide expertise but cannot vote as IRB members (21 CFR 56.107(f)).

Under 21 CFR 812.150(a)(2), the investigator must report the withdrawal to the sponsor within 5 working days. Stop activities no longer authorized by the IRB and assess appropriate care and follow-up for enrolled participants. The investigator's notification is distinct from the sponsor's separate duty to notify FDA, other reviewing IRBs, and participating investigators. Preserve the written IRB decision and records of all subsequent actions.

Confirm why the treatment was given, its actual dates and doses, whether the protocol's rescue criteria were met, and any effects on safety monitoring or endpoints. Do not discourage medically indicated care merely because it affects the trial. Record the concomitant intervention, discuss implications with the investigator, and report deviations where applicable. Analysis of the rescue intervention should follow prespecified trial rules, not after-the-fact preference for more favorable results.

Evaluate the conflict with the blinding and independent-review plans before allowing access or participation. Preserve separation of unblinded comparative information from blinded decision-makers, select an appropriate replacement or safeguards, and document the decision. If information was already shared, assess and contain the breach and consider whether previous endpoint decisions need independent review. Job titles alone do not ensure functional independence.

Limit further access immediately, preserve evidence of the transmission, and establish who saw which treatment assignments. Notify the investigator and sponsor, assess effects on safety, endpoint assessment, and trial integrity, and implement a documented mitigation plan. Do not delete audit evidence, silently reassign roles, or pretend the information was never disclosed.

Apply the definitions in the currently approved protocol, statistical analysis plan, and study reporting procedures rather than choosing whichever date makes the dashboard look complete. Separate treatment discontinuation, last protocol-required safety assessment, participant withdrawal, primary outcome completion, and overall study completion where relevant. Explain any out-of-window or unscheduled assessments in the appropriate records, preserve the true observation dates, and align site and sponsor reporting. Consistent definitions matter for endpoint completeness, database finalization, and public registration timelines.

Reconcile the actual staff responsibilities and dates against the delegation and training records, review the unresolved findings with the investigator, and record their significance, corrective actions, owners, and follow-up deadlines. The monitor should assess source-data availability, consent documentation, investigational-product disposition, safety follow-up, and plans for archival access as part of the closeout assessment. ICH E6(R3) section 3.11.4.5.2 supports confirming essential-record retention and final product accountability during site closeout. A closeout visit does not erase findings or constitute evidence that unresolved compliance issues were corrected.

The arithmetic balances, but the site must verify that the figures represent distinct units and are supported by dated receipt, dispensing, participant return, transfer, return-shipment, and destruction records. A kit initially dispensed and later returned by a participant must not be counted as two different final dispositions. Reconcile lot and kit identifiers, quantities, custody, and participant assignments and investigate any unexplained differences. Under 21 CFR 312.62(a) and 312.59, records of drug use and the sponsor-authorized disposition of unused supplies must be maintained. Matching totals alone do not prove traceable accountability.

No. Implantation may be the intended final disposition. The investigator should retain device identification, serial or lot identifiers, recipient exposure and relevant use records, and any ongoing device-surveillance or medical follow-up obligations. Account for unused, explanted, repaired, returned, or destroyed devices separately, including reasons for disposition when required by 21 CFR 812.140(a)(2). Do not order unnecessary device removal merely to close a log. Any recall, explant recommendation, or post-study safety action requires appropriate clinical, sponsor, and regulatory evaluation.

Inventory and categorize the remaining materials, isolate hazardous and potentially biohazardous waste, and follow sponsor-approved product disposition plus institutional occupational-safety and environmental procedures. Use authorized trained handlers rather than transferring exposed sharps through ordinary courier routes. Preserve product identity, destruction evidence, and accountability records for items subject to study tracking. Confirm that no investigational materials are inadvertently left in routine clinical stock, and document that each storage and treatment area has been cleared. Study closeout never overrides waste-handling and worker-protection requirements.

Locate and organize existing original records and explain genuinely missing documents without creating them retroactively. If a truthful late entry is needed, identify its actual author, date, source, and reason, following site procedures. Provide the monitor a clear reconciliation of outstanding records rather than producing backdated forms for a clean-looking file.

Appropriate secure storage, temperature monitoring, trained responsible staff, and instructions for handling storage excursions and documenting receipt.

Yes. A breach exposing identifiable sensitive research data may be unexpected, related to the research, and create greater privacy, economic, or social risk than previously recognized. Evaluate harm, contain the incident, and make prompt notifications under applicable IRB, regulatory, institutional, and privacy procedures; physical injury is not required.

No. 21 CFR 312.7 forbids promotional claims that an investigational drug is safe or effective for its study use and prohibits commercial distribution or test marketing; scientific information may still be exchanged appropriately.

No. Section 50.24(d) requires a separate IND or IDE that clearly identifies the protocol as potentially enrolling participants unable to consent, even when the product already has an IND or IDE.

Yes. Under 45 CFR 46.102(e), obtaining, using, studying, analyzing, or generating identifiable private information about living people may constitute human-subject research without direct interaction.

Generally no; an immediate change necessary to eliminate an apparent hazard to participants may be made first and then reported as required.

Yes, but the 21 CFR 50.53 category permits only a minor increase over minimal risk, requires experiences reasonably commensurate with the children's situation, and must yield vital knowledge about their disorder or condition, with assent and permission safeguards.

Treat it as a data-quality signal rather than proof of falsification. Compare visit timing, measurement methods, equipment records, and selected source notes; seek explanations and use targeted monitoring or audit if risk warrants. Document findings and corrective measures while preserving original data and ensuring that legitimate values are not changed merely because they appear unusual.

Treat the pattern as a potential signal of incomplete assessment or reporting, compare it with visit notes and comparable sites, and seek an explanation. If warranted, conduct targeted source review, retraining, or an on-site review; zero reported events alone neither proves safety nor misconduct.

No. Waiver of documentation under 21 CFR 56.109(c)(1) removes the signature requirement in eligible minimal-risk research with no procedures normally requiring written consent outside research; the underlying consent process remains required unless separately waived.

No. An ownership interest whose value cannot be readily determined by reference to public prices is significant under the rule regardless of a $50,000 public-market threshold.

No. Certain eligible studies no longer require continuing review unless the IRB determines otherwise; applicable FDA and other rules must also be considered.

No. Applicable regulatory authorization and IRB/IEC review are separate requirements.

No. The study must satisfy all applicable exemption conditions under 21 CFR 312.2(b); marketing approval alone is not sufficient.

An emergency deviation intended to protect a participant's life or physical well-being must be reported by the investigator to the sponsor and reviewing IRB as soon as possible, but no later than 5 working days after the emergency under 21 CFR 812.150(a)(4). The sponsor also has a separate FDA notification duty under the applicable IDE change provisions. Record why the deviation was necessary, what was done, and the clinical outcome.

Use the protocol's controlled emergency unblinding process, disclose only what is needed for care, and document the rationale, time, participant, person accessing the code, and notifications. Ensure care is not delayed and protect blinding of other staff and outcome reviewers wherever feasible.

Ask the investigator or qualified designee to reassess the participant's understanding in a noncoercive discussion, explain the assigned-treatment possibilities and alternatives accurately, and allow questions and a genuine choice about continued participation. Document the concern, the discussion, and the participant's decision. Assess whether the misunderstanding suggests a broader consent-process problem that should be reported or corrected under the IRB's procedures; do not assume the original signature settles the issue.

Under 21 CFR 312.55(b), keep participating investigators informed of new observations concerning the investigational drug, particularly adverse effects and safe use. Communicate meaningful information promptly through suitable updates or safety notices, and meet any separate IND safety-reporting requirements. Sites should evaluate the implications for participant care, consent, and IRB communications. A change occurring outside the United States is not automatically irrelevant.

Critical trial evidence must remain complete, attributable, and accessible for authorized inspection or review even as vendors and systems change. Identify the essential records and relevant metadata held in each system, assign custody, confirm retention and export rights, and test retrieval before access ends. Document any approved transfers and gaps, with escalation for records that cannot be obtained. A final eCRF export alone may not reconstruct protocol compliance, product exposure, consent history, or source measurements throughout the study.

Evaluate an information amendment under 21 CFR 312.31 for essential chemistry, manufacturing, control, toxicology, or other technical information not properly handled through a protocol amendment, IND safety report, or annual report. Identify the amendment's nature and purpose and provide an organized scientific submission. The regulation states such amendments should be made as needed, but where feasible not more often than every 30 days. Independently assess whether the finding affects product disposition, subject safety, or ongoing dosing; the filing category does not replace immediate protective action.

Identify every conflicting controlled document, stop or verify affected dosing decisions before further use, and have the investigator assess participants potentially exposed to outdated instructions. Replace obsolete working materials, retrain relevant staff, reconcile effective dates, and document deviations and corrective actions. A protocol version should not be considered implemented merely because an approval letter was filed.

Stop further use until the equipment's status is resolved, evaluate the validity of results collected during the affected period, and notify the investigator and appropriate quality personnel. Follow documented maintenance, calibration, and corrective procedures; repeat assessments only when safe and protocol-permitted. Do not backdate calibration or assume that all recorded values are reliable.

Do not sign an untrue completion statement or backdate the missing work. Identify the checks that were not done, evaluate whether their absence threatens participant protection, source-data traceability, or inspection readiness, and complete them where feasible. Disclose residual deficiencies to the sponsor and investigator with a documented corrective or risk-mitigation plan. The certification should describe verifiable status, including any exceptions. Accurate contemporaneous evidence is more valuable than a superficially clean checklist; falsifying completion creates an additional serious data-integrity problem.

The monitor may identify a discrepancy and raise a query, but should not impersonate site personnel or make an investigator-attributed clinical source entry. Corrections must be performed or authorized by the appropriate accountable individual, preserve the original entry, and record who changed what, when, and why. Monitoring must remain independently verifiable rather than fabricating clinician authorship. Investigate any prior shared access or unauthorized changes and correct the underlying access controls before further reliance on the records.

Perform a traceable medical and data reconciliation before treating the case as final. Compare case identifiers, event terms, seriousness, onset and resolution dates, outcomes, and follow-up source information; resolve discrepancies through authorized medical review and site queries. Update each system with supported facts while preserving an audit trail and the investigator's clinical assessment. Confirm any additional reporting obligations that arise from corrected information. Both databases should tell a consistent and verifiable safety story; agreement must not be achieved by overwriting records without evidence.

Required study records remain subject to applicable retention and inspection rules after study completion. Under 21 CFR 812.145, FDA has inspection and copying authority for the required IDE records; under section 812.140, the investigator and sponsor must maintain the records for the prescribed period. Contact the identified custodian, verify the requester's authority, arrange timely access in a manner consistent with confidentiality protections, and document the request and response. The location of an archive does not excuse lost records, indefinite delays, or a refusal to provide appropriately authorized inspection access.

Obtain the sponsor's documented release or restart instructions, the investigator's safety assessment, and any conditions set by FDA, the IRB, or other applicable oversight bodies. Confirm affected product is suitable for use, required corrective measures and training are complete, and participants can be managed safely. Do not interpret an informal conversation as authorization to disregard a formal hold or suspension.

Generally no. For changes covered by 21 CFR 312.30(b)(1), the sponsor must submit the amendment to FDA and the IRB must approve the change; these conditions can be completed in either order, but routine implementation waits for both. The narrow immediate-hazard exception is separate. Track approvals and the effective protocol version for each site before changing participant-facing procedures.

Not automatically. Under 21 CFR 312.42, a clinical hold can apply to one or more investigations covered by an IND, so the sponsor must establish the precise FDA order and communicate which protocols and activities it affects. At affected sites, no new participants may be recruited and given the investigational drug; participants already receiving it ordinarily stop that treatment unless FDA specifically permits continuation for safety. Maintain clinically necessary care and required follow-up, and do not extend or narrow the hold based on assumption.

Verify the record class and all applicable retention triggers, sponsor instructions, contracts, institutional schedules, product-development obligations, privacy laws, litigation holds, and any ongoing investigation. ICH E6(R3) section 3.16.3(b) advises that the sponsor tell investigators in writing when trial records are no longer required under the applicable rules. Authorize secure destruction only after all controlling obligations have expired and document the approval, scope, date and method. An archive vendor cannot decide independently that a study is legally disposable just because its local storage timer has elapsed.

The sponsor reports qualifying information to FDA and participating investigators as soon as possible, generally no later than 15 calendar days after determining it qualifies for reporting (21 CFR 312.32(c)(1)). This sponsor obligation is distinct from the investigator's immediate serious-event reporting to the sponsor.

The investigator or sponsor must retain required records during the study and for two years after the later of trial termination or completion, or the point when the records are no longer needed to support specified regulatory submissions, including a premarket approval application, product-development-protocol completion notice, humanitarian device exemption, 510(k), or De Novo request. Because the supporting regulatory need has not ended, two years after the study end may be too soon. Document the controlling later milestone and check any additional institutional or contractual preservation requirements.

It is a qualifying human drug or device study in a marketing application or reclassification petition relied on to establish effectiveness, or a study in which one investigator significantly contributes to showing safety; not every research study qualifies.

Assess the effect on the completeness and timing of critical outcome data, then introduce feasible controls consistent with the protocol, such as validated offline capture, participant support, and targeted follow-up. Confirm that timestamps and original responses remain traceable. Update the risk assessment, monitoring priorities, and instructions to affected sites. Do not create retrospective diary entries on participants' behalf.

Document the provider's qualifications, delegated activities, training, specimen handling, privacy safeguards, safety escalation, and investigator/sponsor oversight; contracting a vendor does not remove trial responsibilities.

With IRB concurrence in the NSR determination and IRB approval, while complying with abbreviated IDE requirements; prior FDA approval of an IDE application is not ordinarily required.

A screening log tracks assessed candidates and screening outcomes to evaluate recruitment and reasons for screen failure; a confidential enrollment or identification log links assigned study IDs with the enrolled participants. Keep identifiable information access-restricted and follow protocol, IRB, and privacy requirements for each record.

Monitoring is an ongoing sponsor oversight and quality-control activity focused on participant protection and reliable conduct and data. A sponsor audit is a systematic, generally independent quality-assurance examination of compliance and processes. An FDA inspection is an authorized regulatory examination to assess compliance and data integrity; passing routine monitoring does not replace either one.

The TMF contains or references essential trial records; the ISF is the investigator/institution's repository for site-relevant essential records needed for oversight and inspection.

A pivotal study is designed to provide the principal evidence of device safety and effectiveness for its specified intended use, often to support a marketing submission; feasibility work is exploratory.

The protocol describes trial design and conduct; the SAP details prespecified analysis methods and should be finalized before relevant unblinding or data analysis.

Allocation concealment prevents foreknowledge of upcoming assignments; blinding limits awareness of assigned treatment after assignment.

Assess timing, alternative causes, medical history, concurrent treatments, and available pharmacologic and clinical evidence. Under 21 CFR 312.64(b), serious-event reports to the sponsor include the investigator's assessment of whether a reasonable possibility exists that the investigational drug caused the event; the sponsor then evaluates the overall safety information.

Parental or guardian permission provides legally required authorization, while assent is the child's affirmative agreement when applicable.

Source-data verification compares specified reported values with original supporting records for accuracy and completeness. Source-data review evaluates the context and quality of source documentation, including protocol compliance, safety information, and whether the story of the participant's care is consistent; monitoring intensity should be risk-proportionate.

Section 50.24 allows prospective IRB approval of a qualifying emergency-research protocol without consent for all subjects and requires special safeguards, including community consultation, public disclosure, and independent data monitoring; section 50.23 addresses qualifying emergency use.

A DSMB provides independent ongoing review of accumulating trial data and may recommend continuation or modification; an IRB/IEC provides independent ethical review and approval and oversees participant protections within its regulatory remit.

Maximize possible benefits and minimize foreseeable risks through a favorable risk-benefit assessment.

With an IRB-approved written consent form signed and dated by the participant or legally authorized representative at the time of consent; a copy must be given to the signer (21 CFR 50.27(a)).

At least three years after completion of the research, with records accessible for FDA inspection and copying at reasonable times (21 CFR 56.115(b)); other obligations may require longer retention.

Complete and document eligibility before initiating the allocation request, and use the protocol-specified, access-controlled assignment process. Staff making enrollment decisions should not be able to predict or manipulate the next assignment. Keep the sequence or system credentials restricted and maintain a traceable record of who randomized the participant and when.

In understandable language suited to the prospective participant, without coercive or exculpatory wording.

It should specify exactly what is measured, how it is measured, and when, so all sites apply the same outcome definition.

The sponsor retains overall responsibility for trial quality and integrity and should maintain appropriate oversight of transferred activities.

Check the technician's authorized role and whether the discussion or their participation could transfer unblinded information to blinded staff. Keep operational preparation duties separated from treatment-comparison discussions unless the protocol and data-access plan permit the role. Document any required safeguards, training, and actual exposure to treatment information.

The individual research participant's rights, safety, and well-being.

Apply the protocol's dose-limiting toxicity definition and assessment window separately from the regulatory seriousness test. Promptly alert the investigator and dose-escalation review body as specified, assess participant safety, and document the clinical evidence. The finding may stop escalation or alter the next cohort even if it is not a serious adverse event. Continue routine or expedited adverse-event reporting if separately required. Treating 'DLT' and 'SAE' as synonyms can cause both unsafe escalation decisions and inaccurate safety data.

Do not open or dose the next cohort until the defined safety data, review quorum or decision-makers, stopping rules, and authorization criteria have been satisfied. Record the decision and any unresolved safety issues; recruitment pressure cannot override the protocol's escalation gate.

No. Although protocol-defined endpoints such as mortality are ordinarily reported under the protocol's endpoint framework, 21 CFR 312.32(c)(5) preserves IND safety reporting when a serious and unexpected event has evidence suggesting drug causation. A death from suspected drug-induced anaphylaxis may therefore need both endpoint documentation and an IND safety report. Keep the endpoint assessment, medical case details, causality evaluation, and reporting pathways linked without assuming that designation as an endpoint removes a safety obligation.

Under 21 CFR 812.140(a)(3), maintain accurate records of the participant's exposure to the investigational device, including the date and time of each use and any other therapy, together with relevant clinical observations and adverse device effects. Capture the additional surgery and treatment as relevant to safety and interpretation, not merely the implantation date. Keep source evidence that links the device and clinical course to the correct participant.

Not solely because the packaging appears intact. Secure or quarantine the affected drug, investigate who might have accessed it, and check storage and accountability records and any exposure to unsuitable conditions. Ask the responsible pharmacy or sponsor personnel to determine documented suitability for further use; do not presume tamper evidence or quality based on appearance. Address access-control failures and evaluate whether any affected participant previously received compromised stock.

The site should not treat an expired approval as continuing authorization for research interventions. Contact the reviewing IRB and sponsor immediately, verify whether any documented action restores approval, and follow applicable requirements and IRB instructions before additional research dosing or enrollment. At the same time, the investigator must protect participants: arrange appropriate clinical care, assess risks from interruption, and seek ethics or regulatory guidance on activities needed for participant welfare. Record the lapse and any required reports; do not retrospectively label treatment as approved.

No. The defined category generally covers controlled trials of qualifying FDA-regulated drug or biologic products other than Phase 1 investigations; other laws, funders, or journal rules may still require registration.

No. Form FDA 1572 pertains to drug investigations under an IND; applicable device-investigator agreements are addressed under 21 CFR 812.43.

No. Under 45 CFR 46.306, the institution must certify appropriate IRB review, and the HHS Secretary's determination must cover a permitted research category; additional prisoner protections apply.

No. Under 21 CFR 812.43(b), investigational devices may be shipped only to qualified investigators participating in the investigation; receipt arrangements must support controlled handling.

No. An IRB member with a conflicting interest must not participate in the initial or continuing review, other than providing information the IRB requests (21 CFR 56.107(e)).

No. Under 21 CFR 11.100, each electronic signature must be unique to one individual, not shared or reassigned, and the person's identity must be verified before the signature is authorized.

Not always. Under 21 CFR 50.55, the IRB may find assent unnecessary if the child cannot reasonably be consulted or a crucial direct-benefit intervention is available only in the study; it may also waive assent when documented minimal-risk waiver criteria are met.

Promptly communicate material new information in an understandable way, follow sponsor/IRB instructions on implementation, and obtain updated informed consent from affected participants when required before further relevant activities. Document the discussion, decisions, form versions, and any urgent safety measures; a signature alone is not the whole process.

No. Study supplies must move through a sponsor-authorized and documented distribution process that preserves labeling, chain of custody, environmental requirements, and product accountability. First confirm that site-to-site transfer is permitted under the sponsor's system, applicable regulatory arrangements, and product-handling instructions. Record dispatch, receipt, lot or kit identifiers, and any temperature data. If timely compliant supply cannot be arranged, alert the investigator for an authorized participant care plan rather than making undocumented transfers.

Maintain controlled version identifiers and effective dates, reconcile sponsor and IRB approvals, archive superseded copies, and release only the authorized versions for training and participant use.

Assess whether the problem stems from device performance, unclear instructions, inadequate competence, or an unsuitable workflow. For high-risk participant procedures, restrict performance to qualified personnel until effective remediation and competency verification occur. Evaluate participants already exposed and whether the failed recordings affect safety or endpoints, then involve the sponsor and IRB as applicable. Document observed performance and corrective action, not merely a second attendance signature. Training completion does not by itself demonstrate sustained competence.

Investigate why the problem recurs, such as unclear directions, language barriers, timing, or inadequate confirmation. Assess impact on participant safety and test validity, revise the workflow or materials through approved controls, document corrective and preventive actions (CAPA), and verify that the changes work.

Evaluate the aggregate pattern across participants, sites, doses, background rates, and other available evidence to determine whether it suggests a new safety risk or a causal association. Use qualified medical and statistical review as appropriate, update risk mitigation and safety communications when warranted, and follow applicable reporting rules. Site-by-site judgments do not replace sponsor-level signal evaluation.

Establish whether the update changed acquisition, calibration, algorithms, units, timing, or data export in a way that affects measurement comparability. Preserve the version used for each observation, validate or verify the updated workflow as appropriate, and assess any protocol, sponsor, ethics, or device-regulatory change requirements. If comparability cannot be demonstrated, flag affected endpoints for the prespecified statistical and quality review rather than silently merging them. An automatic vendor update is still a controlled change when it alters critical trial data.

The investigator retains responsibility for trial activities delegated under the investigator's authority, even if the sponsor helped identify or pay the provider. The investigator should be able to judge the nurses' suitability, receive important findings promptly, and ensure appropriate clinical oversight and reporting. The sponsor separately remains responsible for its own oversight obligations and for the quality of any transferred sponsor activities.

Retain the original timestamps, recorded time zones, device settings, and any daylight-saving transition details. Establish a documented, validated conversion to a common reference for the study analysis and assess whether event or dosing order changes. Do not overwrite the original time simply to make systems visually agree. If the discrepancy affects protocol windows or a pharmacokinetic endpoint, escalate the interpretation and preserve the full audit trail of any corrected derived time.

No. An unmonitored interval cannot be presumed compliant. Identify the affected specimens, times and shipping conditions, obtain available supporting evidence, and consult the receiving laboratory's acceptance criteria. Document whether samples can be analyzed with qualification, require repeat collection, or must be excluded from a particular assessment.

Notify the investigator promptly so participant safety can be assessed using available information and a timely repeat test or other clinically appropriate evaluation. Document the rejected specimen, the reason for rejection, and any resampling. Do not substitute an older normal result as though it met the current protocol safety requirement.

Verify the original source entry and relevant clinical context, correct the eCRF through the approved process with an attributable audit trail, and determine whether the discrepancy affects safety or eligibility. Preserve the original record and avoid changing source data solely to agree with the eCRF.

A clinical study report should accurately integrate the trial design as conducted, significant protocol changes, rationale and timing of amendments, relevant deviations, prespecified versus revised analyses, and any impact on interpretation. Omitting an endpoint-timing change can conceal a source of bias or make the results difficult to reproduce. Investigate the approved amendment and statistical analysis plan history, report the modification transparently, and explain whether analyses were adjusted before or after relevant unblinded information became available. ICH E6(R3) section 3.17.2 points sponsors to ICH E3 or applicable standards for trial reports.

No. Preserve the investigator's medically reasoned assessment and the sponsor's independent evaluation with their respective dates and supporting facts. Under the IND rules, the sponsor is responsible for assessing expedited safety-reporting criteria and may reach a different causality conclusion from the investigator. Communicate the disagreement clearly, investigate additional evidence, and submit required reports without rewriting the original clinician's attribution. Any correction of a factual error should be traceable, not disguised as consensus.

No. All permitted storage and dispensing locations must be included in the inventory and disposition reconciliation, including satellites and delegated pharmacies. Obtain original accountability and shipping records, verify whether any stock remains at the infusion clinic, and ensure secure disposition and documentation of products found there. Assess whether the missing logs indicate a broader oversight or traceability gap. A site-wide declaration must be supported by all relevant custodians, not merely the central pharmacy's inventory.

Review the approved protocol, current informed consent, IRB/IEC determinations, specimen-management plan, data-sharing or biobank agreements, and applicable privacy and biosafety laws. Determine which materials must be retained, which may be used for approved future work, and which require disposal or specific withdrawal-related handling. Document specimen identifiers, location, authorization, and actual disposition. A completed primary analysis is not, by itself, permission to destroy or retain specimens contrary to participant permissions and governing requirements.

No. Identify responsibilities that require the qualified investigator's review or attestation, establish an authorized and documented succession or transfer arrangement, and complete required sponsor, institutional, and IRB notifications. Where permitted, an appropriately qualified successor should assume responsibilities through the proper procedures; coordinator delegation does not automatically transfer overall investigator accountability. Preserve who reviewed and approved data and identify the long-term custodian of the site's essential records. ICH E6(R3) section 2.12 specifically addresses keeping the sponsor informed of the records custodian if an investigator leaves.

Establish qualified medical coverage with authority to make protocol-required decisions, clear escalation contacts, appropriate documented delegation, and any sponsor or regulatory notifications needed for the change. The investigator should ensure continued supervision of participant safety and data quality. If an investigator is formally replaced, confirm whether an updated investigator agreement, IRB documentation, or IND submission is necessary.

A responsible party that becomes aware of an error in submitted clinical trial registration information generally has no more than 15 calendar days to correct or address it under 42 CFR 11.64(b)(2)(i). Do not wait for the next yearly verification. This correction deadline is distinct from the update deadlines for certain legitimate trial-status changes; the applicable regulatory category matters.

No. A total-count match cannot substitute for unit-level and participant-level traceability when those records are required. Reconstruct dispensing, returns, transfers, and any documented loss from the source materials; interview responsible personnel; and document the investigation and any unresolved discrepancy. Assess possible implications for participant dosing, product diversion, blinding, or the integrity of compliance data. Report and manage the issue under sponsor procedures, then archive the evidence and corrective actions. Never invent a reconciliation entry solely to force a clean final balance.

No. The sponsor must address the SR determination and obtain the required FDA IDE and IRB approvals before the investigation starts.

When appropriate, explain additional costs to participants that may result from research participation; the fact that the investigational product is free does not remove this disclosure consideration (21 CFR 50.25(b)(3)).

Only if the approved protocol and documented contingency procedure explicitly authorize that secure alternative and the appropriate personnel verify the assignment. Otherwise do not improvise, guess, or reveal a concealed sequence. Contact authorized randomization support, protect the participant, and record any resulting delay or missed dosing window accurately.

Removing a safety-monitoring test may significantly affect participant safety. Under 21 CFR 312.30(b)(1), such a change is an example of a Phase 2 or 3 protocol modification that calls for a sponsor amendment to FDA, plus IRB approval before routine implementation. The sponsor should justify how safety will still be protected and provide sites with updated instructions; a workload-saving argument is not enough.

Escalate the inconsistency to the responsible sponsor, investigator, and institutional contacts; reconcile procedures against applicable requirements and document a clear, trained reporting pathway.

Use the committee's prespecified disagreement-resolution method, such as an additional independent reviewer or a defined consensus process. Retain the underlying assessments, relevant source evidence, and final documented outcome. A coordinator or sponsor employee should not choose whichever classification favors the trial hypothesis. Consistent application of definitions protects the credibility of endpoint data.

Protect both participants' identities and preserve their underlying source records, then trace which visit data, samples, and treatment records belong to each individual. Use the sponsor's controlled identifier-correction or merge process with an audit history and documented reconciliation. Never solve the problem by deleting one participant record or arbitrarily moving outcomes between records.

No. Do not infer identity from memory or the order in which tubes were placed on a tray. Quarantine or invalidate the unidentifiable specimens according to laboratory procedures, protect participants from any resulting erroneous clinical decisions, and arrange approved recollection if appropriate. Document the mix-up, reporting, and actions taken.

When the IRB finds that risks are no greater than minimal and adequate provisions exist for children's assent and parental or guardian permission under 21 CFR 50.55.

Among other conditions, the testing must be noninvasive, avoid significant-risk invasive sampling, introduce no energy by design or intention, and avoid unconfirmed clinical diagnosis; the applicable labeling requirements must also be met.

The responsible party must generally submit registration information no later than 21 calendar days after the first participant is enrolled; other requirements may call for earlier registration.

The investigator retains responsibility for delegated work under their control and should ensure appropriate qualifications, clear responsibilities, adequate information, and oversight proportionate to the importance of the activities.

Not automatically. Preserve the excursion and quarantine history, distinguish affected and unaffected identifiers, and obtain disposition or shipping instructions from the sponsor and qualified pharmacy personnel. Confirm packaging, temperature-control and hazardous-material requirements for the return, and document chain of custody and quantities. Do not silently release the quarantined kits to routine use or discard them as ordinary waste. Final accountability should demonstrate exactly what happened to the compromised material and why its ultimate disposition was authorized.

The sponsor must notify FDA as soon as possible and no later than seven calendar days after initially receiving the information (21 CFR 312.32(c)(2)). 'Life-threatening' means immediate risk of death as the event occurred, not an event that could have been fatal if it had been more severe.

The form must explain whether compensation and medical treatment are available for a research-related injury, what they include if available, or where further information can be obtained (21 CFR 50.25(a)(6)).

A concise overview of the trial's objectives, design, population, interventions, key assessments, and duration; it does not replace the full protocol.

The label must state 'CAUTION—Investigational device. Limited by Federal (or United States) law to investigational use.' It must also include other applicable label information and relevant warnings.

The prescribed statement explains that a description of the trial will be available on ClinicalTrials.gov, will not identify participants, and may include a summary of results; use the exact regulatory statement in actual consent documents.

The agreement includes relevant qualifications and a commitment to follow the investigational plan and applicable requirements, supervise device testing, and ensure informed-consent requirements are met.

Fitness for intended use, appropriate user permissions and training, protection of data integrity, traceable corrections or audit trails, and clear source-data arrangements.

At minimum, attendance, IRB actions, votes for/against/abstaining, reasons for required changes or disapproval, and a summary of controverted issues and their resolution (21 CFR 56.115(a)(2)).

Discontinuing the investigational intervention does not always mean ending follow-up; the protocol should explain permitted follow-up while respecting the participant's choices.

An adverse event is an untoward medical occurrence associated with drug use without necessarily implying causation. A suspected adverse reaction requires evidence supporting a reasonable possibility that the drug caused the event. The sponsor uses this distinction, along with seriousness and unexpectedness, when assessing expedited IND reports (21 CFR 312.32).

System validation to ensure accuracy, reliability, consistent intended performance, and the ability to identify invalid or altered records; the validation should be appropriate to the system's intended use.

False or misleading labeling and statements that imply the investigational drug is safe or effective for the use under investigation.

Investigational New Drug (IND) applications and the clinical investigation of drugs and biological products under an IND.

Institutional Review Boards reviewing FDA-regulated clinical investigations.

Investigational Device Exemptions (IDEs) and clinical investigations of medical devices.

U.S. Department of Health and Human Services regulations for protection of human research subjects, including the Common Rule and applicable subparts.

Whether a site can realistically recruit eligible participants and execute the protocol with appropriate staff, facilities, equipment, and resources.

Tailor processes and controls to the importance of the risks to participants and the reliability of trial results.

Among other obligations, personally conducting or supervising the study, following the investigational plan and regulations, ensuring IRB oversight and informed consent, and reporting adverse experiences to the sponsor.

The attestation records the responsible investigator's appropriate review and confirmation of data submitted under the site's responsibility, according to the study's defined process. Before signing, the investigator should have access to the relevant current data, significant query resolutions, corrections and safety information and be able to identify unresolved issues. An automated or delegated signature must not falsely imply personal review. Ask the sponsor to provide an appropriate review opportunity and document any remaining exceptions. ICH E6(R3) emphasizes investigator oversight, traceable changes, and reliable finalization of trial data.

That the specified reportable financial interests and arrangements are absent for clinical investigators in covered studies, as certified by the applicant.

Certification of compliance with applicable ClinicalTrials.gov registration and results-reporting requirements for FDA submissions that require the certification.

Under 45 CFR 46.204, investigators must address appropriate prior risk evidence, minimize fetal risk, meet direct-benefit or restricted minimal-risk/no-direct-benefit conditions, and obtain the consent required by the specific benefit scenario. Pregnancy alone does not automatically prohibit research.

Build quality into the trial's design and processes, focusing attention on factors critical to participant protection and reliable results.

The fair distribution of research burdens and benefits without exploiting convenient or vulnerable groups.

Respect individual autonomy and provide additional protections for people with diminished autonomy.

For investigations under 21 CFR 50.53 or 50.54, the study must meet the ward-related conditions, and the IRB must appoint an independent advocate to protect each ward's interests (21 CFR 50.56).

It is a systematic investigation, including development, testing, or evaluation, designed to develop or contribute to generalizable knowledge (45 CFR 46.102(l)). Whether an activity is labeled quality improvement does not by itself decide its status.

The voluntary consent of the human participant is essential.

Prepare accurate protocol identifiers, study design, interventions, target enrollment, eligibility, locations, recruitment status, outcome measures, sponsor/responsible-party details, and applicable IRB or FDA identifiers (42 CFR 11.28).

It should generate accurate and complete human-readable and electronic record copies for FDA review and protect records so they remain accurately and readily retrievable through the applicable retention period (21 CFR 11.10(b) and (c)).

Dated written approval or favorable opinion and the approved versions of the protocol, consent materials, and other participant-facing information as applicable.

A trial attribute fundamental to participant protection or to the reliability and interpretability of results, identified prospectively. Correct eligibility decisions or accurate primary-endpoint collection may be CTQ factors for a particular study.

A departure from the approved protocol or specified study procedures that should be assessed and documented under applicable requirements.

Proactively identifying critical-to-quality factors and designing processes that prevent important errors before a study begins.

An individual who both initiates and conducts a clinical investigation and therefore assumes applicable responsibilities of both sponsor and investigator.

A controlled written instruction describing how a recurring activity should be performed consistently and in accordance with applicable requirements.

A predefined outcome or measure used to assess an effect or answer a research question.

A record that permits evaluation of trial conduct, compliance, and reliability of the data and results.

Language that appears to waive a participant's legal rights or release researchers, sponsors, or institutions from liability for negligence.

An affirmative agreement by a child capable of providing it; silence or failure to object alone is not assent.

Whether participant protections and the research's approval conditions remain appropriate as the study proceeds.

It is the Investigational New Drug Application form used in IND submissions to FDA, identifying the sponsor and information being submitted.

Ongoing communication supporting a voluntary, informed decision to join or remain in research, not merely a signed form.

Phase 1 primarily examines initial human safety, tolerability, dose range, and how the drug behaves in the body. Participants may be healthy volunteers or patients, depending on the product and condition.

An international statement of ethical principles for medical research involving human participants.

An IND supports certain clinical investigations of investigational drugs or biologics; an IDE addresses investigational medical devices.

Expedited review is performed by the IRB chair or designated experienced reviewers for eligible research; it is not an exemption from ethical review.

Correction fixes the immediate problem, such as recovering a missing visit form. Corrective action addresses the demonstrated cause of a detected problem, while preventive measures reduce recurrence or similar failures. An effective CAPA assigns responsibility, records actions and deadlines, and checks whether the risk was actually reduced.

An attendance record shows exposure to instruction; competence may need direct assessment, observation, or role-specific qualification so the investigator can be confident the person can safely perform the procedure.

To independently review and oversee research to protect the rights, safety, and welfare of human participants.

It gathers early clinical information about device functionality, initial safety, and study procedures, often with relatively few participants, to refine the device or plan a later pivotal investigation.

Criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and generally equivalent to paper records and handwritten signatures within its scope.

At least five members with sufficiently varied backgrounds and qualifications to review the research and safeguard participants.

To protect participants' rights, safety, and well-being while ensuring credible clinical trial results.

Protection of human subjects, including FDA informed-consent requirements.

To provide a comparison for interpreting the effects of the intervention under study.

It maps visits, assessments, procedures, and allowable windows, helping sites plan staffing, participant burden, and consistent data collection.

To verify required approvals, current document versions, staff training, study systems, supplies, and operational readiness before the site begins authorized activities.

To identify conditions or characteristics that make participation unsuitable or could compromise safety or interpretability.

The Statement of Investigator records key details and commitments of an investigator participating in a drug study conducted under an IND.

To identify the characteristics participants must have to qualify for the trial.

It compiles relevant clinical and nonclinical information on an investigational product to help investigators understand its rationale, dosing, administration, and safety monitoring.

The sponsor submits the annual report within 60 days after the anniversary of the IND becoming effective. It summarizes the investigation's progress, including study status, participant enrollment and discontinuations, important safety findings, relevant results and other required developments, and the coming year's investigational plan. This periodic report does not replace prompt IND safety reports or required protocol amendments when separate submission duties arise.

Meaningful changes in the safety profile, protocol, trial procedures, technology, service providers, site performance, or completeness of key data can change the original risk assumptions. Reevaluate affected critical-to-quality factors, revise proportionate controls where appropriate, communicate responsibilities, and document the reasons and outcomes. Risk management is maintained throughout conduct; it is not a one-time start-up checklist.

Relevant nonclinical pharmacology and toxicology, product manufacturing and quality information, and the proposed clinical protocols and investigator information.

The investigation meets the criteria in 21 CFR 812.3(m) because the device presents a potential for serious risk to participants, such as certain implanted or life-supporting devices.

Under 21 CFR 50.52, risks must be justified by anticipated benefit, the benefit-risk relation must be at least as favorable as available alternatives, and appropriate assent and parental permission provisions must be in place.

The required IRB/IEC approval or favorable opinion and other applicable authorizations must be in place.

State the required units, collection time points, source location, and conversion or transcription rules so records remain interpretable and consistent with the protocol and case report form.

A written decision stating the reasons for disapproval and offering the investigator an opportunity to respond in person or in writing (21 CFR 56.109(e)).

The sponsor must satisfy the applicable 21 CFR 812.2(b) conditions, including investigational labeling, IRB approval, informed consent, monitoring, records and reports, and prohibitions on promotion.

When appropriate, include the approximate number of participants involved in the study so prospective participants understand the planned study size (21 CFR 50.25(b)(6)).

Under 21 CFR 812.43(d), the sponsor must select monitors qualified by training and experience to monitor the investigation in accordance with Part 812 and other applicable FDA regulations.

Phase 2 studies obtain preliminary evidence of effectiveness in people with the target condition, assess short-term adverse effects, and help refine dose selection and later trial design.

Identify appropriate contacts for research questions, questions about participant rights, and contact in the event of research-related injury; one contact may fill more than one function if appropriate.

It should define membership and independence, the data the board reviews, review timing, confidentiality and unblinding procedures, recommendations, and how safety or stopping concerns are communicated and acted upon.

Participation is voluntary and withdrawal can occur without penalty or loss of benefits to which the person is otherwise entitled.

For each trial duty, identify who performs it, which protocol/product/system and safety topics are required, when training must be completed, and what record demonstrates readiness before the duty is assigned.

Where original data originate and are maintained, which entries are entered directly versus transcribed, who is responsible, and how authorized review and data correction will be traceable.

That the investigator has appropriate education, training, and experience, as well as sufficient time, personnel, facilities, and access to the target population.

Do not begin dosing or other activities covered by the hold; address FDA's concerns and wait for FDA authorization to proceed.

Confirm the planned data cutoff, completeness and status of critical fields, unresolved queries, reconciliations, endpoint definitions, and authorized review or sign-off requirements. Maintain a controlled snapshot with version and access records; later valid updates should remain traceable in the continuing database. A frozen interim extract is not necessarily the final trial database lock.

Safety assessments and frequency, thresholds for action, responsible reviewers, and procedures for escalating or reporting concerning findings.

When appropriate, describe consequences of withdrawal and the procedures for orderly termination of participation, without suggesting the person loses the right to withdraw (21 CFR 50.25(b)(4)).

Stop the affected research activities as directed, protect participants, notify relevant parties, and follow required corrective procedures.

Confirm method suitability, specimen collection and shipping instructions, turnaround times, quality controls, data transfer, and who resolves discrepant results; these arrangements can affect endpoint reliability.

Secure storage, appropriate staff expertise, environmental monitoring, accountability controls, and the ability to prepare and dispense the product as required by the protocol.

Relevant operator training, device-use instructions, maintenance or calibration arrangements when needed, risk controls, and product-handling records.

That the person is appropriately qualified, trained, and authorized, and that the investigator retains appropriate oversight.

Verify the inspector's credentials and coordinate with the investigator and institutional contact, while allowing the inspection and copying of records as required by the applicable regulations. Make authentic records accessible, explain their organization, and protect information appropriately within lawful limits. Do not alter, hide, or destroy records in response to the request.

Use an appropriately qualified interpreter and approved consent materials or procedures to support meaningful understanding.

The participant or representative signs the short form; a witness signs the short form and the IRB-approved oral-presentation summary; the person obtaining consent signs the summary. Copies of both are given to the participant or representative (21 CFR 50.27(b)(2)).

Under 45 CFR 46.304, at least one member must be a prisoner or qualified prisoner representative, and a majority of members other than prisoner members must have no association with the prison except IRB membership.

Repeated looks at accumulating data increase the chance of a false-positive conclusion if testing is not designed to account for them. Interim analyses, boundaries, and information access should be prespecified and overseen by qualified, appropriately independent personnel. Unplanned peeking may also influence conduct. Investigators should not request unscheduled comparative tests simply because early outcomes look promising.

The IRB must assess minimized and reasonable research risks, equitable participant selection, required consent, adequate safety monitoring when appropriate, privacy and confidentiality protections, and safeguards for vulnerable participants (21 CFR 56.111).

Role-appropriate training in the approved protocol, product or device handling, safety escalation, relevant GCP requirements, systems, and applicable procedures.

Maintain traceable records of investigational drug receipt, dates and quantities dispensed or administered, participant or other authorized use, returns, and disposition, with product identifiers as applicable. Under 21 CFR 312.62(a), the investigator must maintain adequate drug-disposition records, including dates, quantity, and use by subjects.

Research on FDA's published expedited-review list that a reviewer finds no more than minimal risk, or minor changes to previously approved research during its approval period; expedited does not mean exempt.

Only authorized individuals should access the system, and authority checks should restrict who may enter, change, review, or electronically sign records according to assigned privileges (21 CFR 11.10(d) and (g)).

Thirty calendar days after FDA receives the IND unless a clinical hold applies, or earlier if FDA notifies the sponsor that the investigation may begin; other required approvals still apply.

Phase 4 follows marketing approval and can examine additional safety information, longer-term outcomes, effectiveness in broader practice, or other questions about use of an approved product.

When specified financial interests or arrangements in a covered clinical study must be disclosed to FDA rather than certified absent.

An IRB may accept one parent's permission for investigations under 21 CFR 50.51 or 50.52. For studies under 50.53 or 50.54, both parents ordinarily must permit, subject to specified exceptions (21 CFR 50.55(e)).

When a life-threatening situation necessitates the article, the patient cannot consent, time does not allow consent from a legally authorized representative, and no equally or more likely lifesaving recognized therapy is available. The investigator and independent physician ordinarily certify the findings in writing before use.

An urgent change necessary to remove an immediate hazard may be made before normal prior approvals, followed by documentation and prompt notification to the sponsor and IRB/IEC or regulators as applicable. For an IDE investigation, 21 CFR 812.150(a)(4) requires notice of the emergency deviation to the sponsor and IRB no later than five working days afterward.

Before conducting study-specific procedures or activities requiring consent, unless an authorized exception applies.

The sponsor should obtain the information before participation; relevant changes must be reported during the study and for one year after study completion.

Under 21 CFR 56.108(b), procedures must address unanticipated problems involving risks, serious or continuing noncompliance, and suspension or termination of IRB approval, with notice to the required recipients.

FDA approval of the investigational device exemption (IDE) and approval by the IRB responsible for that site.

Compensation that increases if the study outcome is favorable; other specified equity interests, proprietary interests, or payments may also be reportable.

The IRB must include at least one member primarily concerned with scientific areas, one primarily concerned with nonscientific areas, and one member unaffiliated with the institution and its affiliated members' immediate families (21 CFR 56.107).

Respect for persons, beneficence, and justice.

An authorized person or process under the institution's and applicable regulatory framework, rather than an investigator simply declaring an exemption.

The sponsor is generally responsible for keeping the IB current and communicating relevant new product information, including safety findings.

The investigator, with appropriately qualified delegated personnel assisting where permitted.

Ordinarily the sponsor; the sponsor may designate a principal investigator who meets the regulation's conditions, including control of trial data, publication rights, and ability to satisfy submission obligations.

It may proceed only through the special 21 CFR 50.54 process involving an IRB finding of a serious pediatric health or welfare problem and an FDA Commissioner determination after expert consultation and opportunity for public review and comment.

Access should be restricted to a designated independent monitoring or statistical group under the data-monitoring plan, with safeguards to prevent disclosure that could bias trial conduct or assessment.

The definition covers the listed or identified investigator or subinvestigator directly involved in subject treatment or evaluation and includes that person's spouse and each dependent child for the financial-interest assessment.

They may face increased risk of coercion, undue influence, or limited capacity to protect their own interests.

They aim to confirm a treatment's benefit-risk profile in the intended patient population, using enough participants to evaluate effectiveness and detect less common adverse reactions in support of regulatory decisions.

Open sessions can cover operational and appropriately masked information with broader trial representatives, while closed sessions may contain comparative or unblinded data restricted to authorized independent members and analysts. This separation supports credible safety and efficacy review without unnecessarily revealing treatment assignments to people conducting the trial. The committee charter should define access and communication pathways; the exact session design is trial-specific.

To link planned enrollment to the study question and statistical assumptions, supporting interpretable results without exposing unnecessary participants to research procedures.

To identify financial interests and arrangements that may bias a covered study, helping FDA assess the reliability of data supporting a product application.

To document which qualified team members are assigned specific study responsibilities and support oversight and accountability.

A useful metric should measure a meaningful risk, use dependable data, be reviewed at an appropriate interval, and have defined follow-up when its signal is concerning. A metric that is ambiguous, delayed, or disconnected from decisions may create false reassurance or unnecessary work. Its purpose is to support detection, escalation, mitigation, and verification, not merely populate a monthly dashboard.

The investigator must have qualifications appropriate to the product, procedures, and participants in the particular study; relevant licenses, clinical expertise, and experience should support that assessment.

To assign treatment groups by chance and reduce selection bias and imbalance from known and unknown factors.

When appropriate, 21 CFR 50.25(b)(2) calls for anticipated circumstances such as a safety issue or protocol-defined termination condition to be explained before consent.

To establish reliable testing capability and support consistent interpretation of laboratory findings used for eligibility, safety, and study outcomes.

The verbatim description retains what was actually reported, while the standardized code supports consistent analysis across participants and sites. Coding should follow approved dictionary and version conventions, with review of ambiguous or clinically important terms. A coding change must not erase the original meaning or silently rewrite the investigator's clinical assessment.

To allow treatment identity to be revealed when needed for participant care while restricting access, documenting the event, and protecting the wider blind.

To ensure necessary data can be collected consistently and evaluated against the trial objectives while avoiding unnecessary fields, participant burden, and site work.

To align trial activities and analysis with the scientific questions while avoiding unnecessary procedures and ambiguity.

A prospective coverage and budget review helps ensure funds and services are available, prevents unexpected participant charges, and makes the consent discussion about additional costs accurate.

The team needs a controlled way to capture required assessments safely during an outage, preserve original entries, and reconcile them into the system without losing dates, authorship, or data integrity.

The basic consent elements require an explanation of the extent confidentiality will be maintained and the possibility that FDA may inspect records identifying participants (21 CFR 50.25(a)(5)).

To prevent avoidable unblinding and bias while retaining an authorized process for emergency disclosure when participant care requires it.

Unnecessary treatment identifiers, post-randomization clues, or unblinded interim results can bias otherwise independent endpoint judgments. Supply standardized, protocol-defined clinical records with identifiers and allocation clues appropriately controlled. Document adjudication decisions and any departures from the charter so the endpoint assessment remains reproducible and interpretable.

To assess whether information and recruitment methods are appropriate, balanced, and protective of prospective participants.

They enable reliable tracking of receipt, inventory, dispensing, return, reconciliation, and final disposition, reducing losses and dosing errors.

Historical patient and enrollment data help distinguish realistically eligible participants from the broader patient population and reduce overoptimistic recruitment estimates.

Prespecified methods support consistent analysis, reduce bias, and avoid choosing a method only after investigators have seen the results.